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ABSTRACT 
Lipids have been utilized to increase the bioavailability of poorly soluble drugs which 
resulted in with advent of High Throughput Screening (HTS). Although lipids have 
been used to improve bioavailability of a few drugs for almost twenty years, they are 
still not well characterized. There are limited publications about the effects of 
physicochemical properties of the lipid vehicle, such as class of lipid (i.e. glyceride, 
propylene glycol ester), fatty acid chain length, MW and polarity on lipid solubility, 
formulation and bioavailability of poorly soluble drugs. Knowledge of such 
relationship can improve quick screening of these vehicles. The goals of this study are 
to identify physicochemical properties of the lipids, to investigate the relationship of 
these properties with solubility of the model drugs, namely nifedipine and 
griseofulvin, to design lipid-drug formulations with Cremophor EL, to evaluate in 
vitro dissolution of selected formulations and to compare the bioavailability of 
nifedipine from the formulations tested. It has been shown that the lipids used 
improved the solubility of nifedipine and griseofulvin compared to the solubility of 
drugs in water. Calculated solubility parameter was not sufficient to predict the 
solubility of the drugs in the lipids. Calculated and measured properties of lipids 
analyzed with stepwise regression analyses showed that MW, dielectric constant, 
surface tension and fatty acid chain length are the common factors that govern the 
lipid solubility. However. the estimates of each factor were different for each drug 
indicating that the nature of the drug played an important role in lipid solubility. 
Incorporation of Cremophor EL. a nonionic surfactant into lipid-based nifedipine 
formulation enhanced the solubility and dissolution of nifedipine. The solubility of 
( 
( nifedipine showed a linear correlation with increasing surfactant concentration. While 
solution rate was dependent on the type of lipid used, the nature of the lipid had no 
affect on the dissolution of nifedipine in presence of the surfactant. Dissolution of 
nifedipine from the lipids showed that as the fatty acid chain length increases, the 
dissolution rate increases. This is due to lower solubility of nifedipine in the lipids that 
have longer chain length. The effect of lipids on dissolution rate and extent of 
nifedipine showed that even though physicochemical properties of lipids (HLB, 
interfacial tension, viscosity, density) and solubility of nifedipine in lipids play a role, 
only partitioning of the drug from lipid to the dissolution medium and the particle size 
of the formulation in dissolution medium provided a good correlation with dissolution 
extent of nifedipine. The bioavailability of nifedipine obtained with different lipid 
formulations in beagle dogs showed that the type lipid and surfactant used in the 
formulation play important roles. Dissolution is a good predictor for in vivo 
performance of nifedipine lipid formulation when it was formulated with non-
digestible lipids (mostly mono-glycerides). Although, the solubility of nifedipine in 
lipids, the particle size of the formulation in dissolution medium and partitioning of 
the drug from the formulation to dissolution medium seem to affect the in vivo 
performance of the drug, dissolution performance of the formulation and digestibility 
of the lipid used in the formulation are the major factors in bioavailability of 
nifedipine from the lipid-based formulations. 
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Section III contains appendices and bibliography, arranged in alphabetic order by the 
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VI 
( 
( 
ABSTRACT 
ACKNOWLEDGMENT 
PREFACE 
LIST OF TABLES 
LIST OF FIGURES 
SECTION I 
TABLE OF CONTENTS 
MANUSCRIPT I: LIPID VEHICLES USED FOR ORAL DRUG DELIVERY OF 
POORLY SOLUBLE DRUGS: A REVIEW ON FORMULATION 
CONSIDERATIONS AND PRODUCT CHARACTERIZATION 
OBJECTIVES 
SECTION II 
MANUSCRIPT II: A PRACTICAL APPROACH TO DETERMINE 
CONTRIBUTION OF MEASURED AND CALCULATED PHYSICAL AND 
CHEMICAL PARAMETERS ON SOL VENT EFFECT OF LIPIDS 
11 
IV 
VJ 
IX 
XI 
79 
80 
MANUSCRIPT III: ROLE OF LIPID PROPERTIES AND CREMOPHOR EL 
CONCENTRATION ON FORMULATION DEVELOPMENT AND DISSOLUTION 
PERFORMANCE OF LIPID-BASED NIFEDIPINE FORMULATIONS 116 
Vil 
MANUSCRIPT IV: BIOA V AILABILITY OF NIFEDIPINE LIPID 
FORMULA TIO NS IN BEAGLE DOGS 
SECTION III 
APPENDIX 
BIBLIOGRAPHY 
VIII 
152 
179 
196 
( LIST OF TABLES 
Section I 
Manuscript I 
Table I: Examples of Commonly Used Lipids in Oral Drug Delivery ... .... ..... .... ........ 49 
Table 2: Properties of Type I, II, IIIA and IIIB Lipid Formulations Based on Pouton 
Classification (Redrawn with the permission of publisher of ref. Pouton, 1999) 55 
Table 3. Lipid Systems: Solution and Suspension ....................................................... 56 
Table 4. Lipid Systems: Micellar Solutions .... .. ... ....... ...................... .. .... .. ................... 60 
Table 5. Lipid Systems: Emulsions and Microemulsions ............................................ 61 
Table 6. Lipid Systems: SEDDS/SMEDDS ................................................................ 63 
Table 7. Lipid Systems: Solid Dispersions/Solutions .................................................. 67 
Table 8. Lipid Systems: Solid Lipid Nanoparticles ... .......... ...... .... ............ .................. 69 
Table 9.Lipid Systems: Cubic Phase .. ..................................... .. ...................... ............. 70 
Table 10. Solubility of griseofulvin and nifedipine in lipid/Chremophor EL mixtures 
······························································································································ 71 
Section II 
Manuscript II 
Table I: Lipid vehicles used in this study ................................................................... 104 
Table II: Group contributions to the energy of vaporization and the molar volume at 
25°C for the functional groups of oleic acid ............................... ....................... 105 
Table III: Experimental solubility results for nifedipine and griseofulvin ................ 106 
Table IV: Calculated and measured properties of lipids used .................................... I 07 
Table V. Linear regression analysis with stepwise fit for solubility of nifedipine .... 108 
IX 
( 
( 
Table VI. Linear regression analysis with stepwise fit for solubility of griseofulvin 109 
Table VII. Effect of hydrophilic head (glyceryl/propylene glycol and# of glyceryl 
group) and lipophilic tail (fatty acid chain length) on solubility of nifedipine and 
griseofulvin analyzed by single factor ANOV A .. ... .... .................. ............. ..... ... 110 
Manuscript III 
Table I. Lipids used in this study ............................................................................... 136 
Table II. Calculated and measured properties of lipids used ..................................... 13 7 
Table III. Nifedipine solubility in Simulated Gastric Fluid at 37°C containing 
Cremophor EL .. ........ ..... ......... .... .... ........ .. ........ ...... ....... ......... .. ..... ...... .... .... ... .. .. 138 
Table IV. Solubility of nifedipine in lipid/Chremophor EL mixtures ....................... 139 
Table V. List of parameters for Equation 2 to investigate the effect of surfactant 
concentration on the solubility of nifedipine (SN) in lipids ................................ 141 
Table VI. Dissolution parameters of nifedipine in various lipids (n =3) ......... ....... ... 142 
Table VII. Results of particle size of nifedipine in each lipid at 37°C ...................... 143 
Manuscript IV 
Table I. Lipid formulations that were used in the in vivo studies .............................. 171 
Table II. Jn vivo study experimental design (crossover study in fasted beagle dogs) 172 
Table III. Nifedipine plasma concentrations (ng/mL) .............. ... ............. .... ...... .. ...... 173 
Table IV. Mean pharmacokinetic parameters of nifedipine lipid formulations with 6 
beagle dogs ......................................................................................................... 175 
Table V. Summary of in vitro results for nifedipine lipid formulations .................... 176 
x 
( LIST OF FIGURES 
Section I 
Manuscript I 
Figure 1. Hygroscopicity of various lipid vehicles ... ... .......................... ... ....... 73 
Figure 2. Effect of HLB on release rate ofRo-0778 .. .... .. ...... ........ .................. 74 
Figure 3. Effect of cooling rate on viscosity of wax based vehicle at different 
temperatures ...................................................................................... 7 5 
Figure 4. Effect of drug concentration on zero shear viscosity and particle size of lipid-
based solution at 25°C ........ ... ... ..... . ...................... ... . .... . . .... ................... 76 
Figure 5. Lipid digestion process ....... .... ... ... ... ........... ..... .. ............ ......... ... 77 
Figure 6. Effect of acyl chain length on the rate of triglyceride lipolysis ................ 78 
Section II 
Manuscript II 
Figure 1. Nifedipine chemical structure ........ ..... .... .... ..... ................................ ........... 111 
Figure 2. Chemical structure of griseofulvin ...... ....................... .............. .................. 112 
Figure 3: Liquid crystal formed with griseofulvin in glyceryl mono-oleate .............. 113 
Figure 4: FT-IR profile of nifedipine in mineral oil and Capmul PG-8 .................... 114 
Figure 5: Effect ofHLB on solubility of griseofulvin ..... ................ ...... ........ ...... ... ... 115 
Manuscript III 
Figure 1. Critical mice lie concentration (CMC) of Cremophor EL (n=3) .............. 144 
XI 
( 
( 
( 
Figure 2. The effect of concentration of Cremophor EL on the solubility of nifedipine 
in lipids .......................................................................................... 145 
Figure 3. Effect of surfactant concentration on dissolution of nifedipine from 
Capmul PG-8 .................................................................................... 146 
Figure 4. Effect of lipid on dissolution of nifedipine ...................................... 147 
Figure 5. Effect of fatty acid chain length on dissolution of nifedipine from propylene 
glycol esters ..................................................................................... 148 
Figure 6. Partition coefficient (oil/water) of nifedipine with different vehicles ....... 149 
Figure 7. Effect of partitioning oflipids from nifedipine formulation to dissolution 
medium on dissolution extent of nifedipine ................................................ 150 
Figure 8: Effect of partitioning and dissolution extent on particle size of the nifedipine 
formulation in lipids ........................................................................... 151 
Manuscript IV 
Figure 1. Nifedipine plasma profiles with four formulations ............................ 177 
Figure 2. Dissolution of nifedipine from the formulations used for in vivo study .... 178 
Section III 
Appendix 
Figure 1. Calibration curve for griseofulvin in acetone ............................................. 180 
Figure 2. Standart curve for HPLC analysis of nifedipine ......................................... 181 
Figure 3. FT-IR spectrum of nifedipine in mineral.. ................................................. 182 
Figure 4. FT-IR spectrum of griseofulvin in mineral.. .............................................. 183 
Xll 
( Figure 5. FT-IR spectrum of oleic acid ...................................................................... 184 
Figure 6. FT-IR spectrum of Captex GTO ....................................... .......................... 185 
Figure 7 FT-IR spectrum ofMiglyol 810 .................................................................. 186 
Figure 8. FT-IR spectrum of Capmul MCM .............................................................. 187 
Figure 9. FT-IR spectrum of Capmul GMO .............................................................. 188 
Figure 10. FT-IR spectrum ofCaprol2GO ................................................................. 189 
Figure 11. FT-IR spectrum of Caprol3GO ................................................................. 190 
Figure 12. FT-IR spectrum ofCapmul PG-8 ............................................................. 191 
Figure 13. FT-IR spectrum of Capmul PG-12 ........................................................... 192 
Figure 14. FT-IR spectrum of Capmul PG-18 ........................................................... 193 
Figure 15. FT-IR spectrum ofCaptex200 .................................................................. 194 
( Figure 16. Standard curve for nifedipine plasma calculation .................................... 195 
Xlll 
( 
( 
Abstract: The advent of High Throughput Screening (HTS) and Combinatorial 
Chemistry in drug discovery has resulted in compounds which are more lipophilic, 
having log P > 4. As a consequence, the application of lipid delivery systems has more 
recently received greater attention in the pharmaceutical industry. This paper presents 
a review of lipid vehicles used in the oral drug delivery of poorly soluble drugs. Lipids 
that are available in the US market are defined and classified and different types of 
lipid formulations have been cited from the literature. Formulation considerations and 
the effect of lipids on lipolysis as well as systemic and lymphatic drug absorption are 
discussed. In addition, the characterization techniques of formulation, stability, in vivo 
I in vitro correlation and absorption mechanisms for lipid-based formulations are 
summarized. 
Keywords: Lipid vehicles, lipid-based formulations, formulation considerations, 
lipolysis, lymphatic absorption, characterization techniques 
Glossary: 
DG: Diglyceride 
DSC: Differential scanning calorimeter 
GER: Gastric emptying rate 
GML: Glyceryl mono-laurate 
GMO: Glyceryl mono-oleate 
GMS: Glyceryl mono-stearate 
HLB: Hydrophile-lipophile balance 
2 
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\ 
IT: Interfacial Tension 
L: Liquid 
LCT: Long chain triglyceride 
LFDS: Low frequency dielectric spectroscopy 
MBLA: N-a-methylbenzyllinoleamide 
MCM: Medium chain monoglyceride 
MCT; medium chain triglyceride 
MG: Monoglyceride 
MP: Melting point 
NI A: Not available 
PEG: Polyethylene glycol 
PGG: Polyglycolized glycerides 
S:Solid 
SEDDS: Self-emulsifying drug delivery system 
SMEDS: Self-microemulsifying drug delivery system 
SEOF: Self-emulsifying oil formulation 
SLN: Solid lipid nanoparticles 
SS: Semisolid 
TG: Triglyceride 
TBUs: Tributyrin units 
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( 1. INTRODUCTION 
During the development of oral pharmaceutical dosage forms of new drug candidates, 
the formulation scientists are faced with many challenges. One challenge which is 
very often encountered is poor bioavailability. With the advent of High Throughput 
Screening (HTS) and Combinatorial Chemistry in drug discovery, modern drug 
molecules are more lipophilic which often results in their being poorly bioavailable. 
The use of lipid vehicles has generated considerable attention in recent years for 
improving the bioavailability of poorly soluble drugs as one of the approaches to 
improve their oral bioavailability. The well-known effect of food in improving the 
bioavailability of many poorly soluble drugs such as griseofulvin, carbamazepine and 
danazol is evidence that lipids can be beneficial to drug absorption (Charman et al., 
1992, 1993, 1997; Humberstone and Charman, 1997). Lipids can improve the 
bioavailability of drugs through several mechanisms such as by enhancing solubility/ 
dissolution (Pozzi et al. , 1991; Sheen et al. , 1991; Charman et al. , 1992; Shah et al. , 
1994; Matuszewska et al., 1996; August et al., 1997), by providing uniform gastric 
emptying and uniform absorption rate (Y amahira et al, 1979a, b, 1980) and by 
increasing lymphatic absorption (Cheema et al. , 1987; Charman and Stella, 1992; 
August et al., 1993; Porter and Charman, 1997). 
Although lipids have been used to improve bioavailability for almost twenty years, 
they are still not well characterized. In addition, mechanistic studies that explain the 
effect of physicochemical properties of lipid vehicles on formulation and drug 
absorption, the use of appropriate techniques to characterize lipid-based systems and 
4 
in vivo/in vitro correlations have not been adequately addressed and well understood. 
In this paper, information regarding these issues is collected and discussed in the 
following order: (I) definition and classification of lipids, (II) type of lipid 
formulations, (III) formulation considerations of lipid based systems, (IV) effects of 
lipids during the absorption of poorly soluble drugs and (V) characterization 
techniques of lipid based systems. 
2. DEFINITION AND CLASSIFICATION OF LIPIDS 
Lundberg and Weiner define lipids as a "chemically heterogeneous group of 
substances, having in common the property of insolubility in water but solubility in 
non-polar solvents" and the science that deals with lipids is referred to as 'Lipidology' 
(Lundberg, 1984; Weiner, 1993). However, many lipids have some limited water 
solubility and are commonly used as vehicles in pharmaceutical formulations. Lipids 
can be classified based on chemical characteristics such as carbon chain length of fatty 
acid and ester type rather than on their solubility. Surfactants also fall into this 
category. Sometimes, there is no distinct difference between a lipid and a surfactant. 
Some lipids have surface active properties, for example medium chain monoglycerides 
can lower interfacial tension and easily dispersed in aqueous media. 
Types of lipids include natural and synthetic fatty acids, oils, fats, waxes, 
phospholipids and some surfactants. Fatty acids can be defined as organic acids with 
straight hydrocarbon chain and can be classified based on the length of the 
hydrocarbon chain. Fatty acids with hydrocarbon length C2-C6 are considered to be 
short~hain, with Cs-C12 medium-chain and with C14 and higher long-chain fatty acids. 
5 
( Oils are unsaturated fatty acid esters of glycerol whereas fats are saturated fatty acid 
esters of glycerol. Waxes are the esters of fatty acids with alcohols other than glycerol. 
Surfactants that are in the lipid category are commonly fatty acid esters of PEGs. 
Lipids also include some lipid fractions and synthetic accommodations of glycerides 
with PEG esters. The fractionated esters are seldom pure and tend to exist as mixtures 
of various combinations. Commonly used lipid vehicles in oral drug delivery have at 
least one fatty acid esterified with a polyol such as glycerol/s, propylene glycol or 
PEG. Tables 1 A-F present lipid vehicles commonly used in the US pharmaceutical 
industry in oral drug delivery products. Phospholipids are excluded from the scope of 
this paper since they are mainly used in parenteral formulations. 
3. TYPE OF LIPID FORMULATIONS 
In addition to simple solutions of drug molecules in lipids, solid dispersions, micelles, 
liquid crystals, emulsions including self-emulsifying systems and microemulsions and 
solid lipid nanoparticles (SLN) are also commonly used formulation approaches for 
lipid based systems. 
Because of their unacceptable taste, many lipid formulations are administered in soft 
or hard gelatin capsules as unit dosage forms. 
Lipid formulations were classified by Pouton (1999 and 2000) as Types I, II, IIIA and 
IIIB. This classification is based on composition such as amount(%) of the glyceride, 
surfactants and hydrophilic co-solvents and physical attributes including particle size 
6 
( of the dispersion, impact of aqueous dilution and digestibility (Table 2). This 
classification can be useful in comparing different studies and can serve as a guide to 
estimate physicochemical properties of the lipid formulation of interest. The 
incorporation of a drug in the vehicle can significantly change the physicochemical 
properties of the system in terms of particle size and dispersibility following aqueous 
dilution and may result in a shift of the system from one type to another. Therefore, 
such classification cannot be a significant predictor of the physicochemical properties 
of the end product and is especially so for surface active and high dose drugs. The 
classification of lipid systems as solutions, suspensions, solid dispersions, micelles, 
emulsions including self-emulsifying systems (SEDDS) and microemulsions and solid 
lipid nanoparticles appears to be universally acceptable. Examples of these 
formulations that are cited in the literature are summarized in Tables 3- 9. As can be 
seen from these tables, SEDDS are the most commonly used formulations and drugs 
with molecular weights around 300 are the most commonly used model drugs. By 
presenting these tables, we wanted give a guideline for the readers. Additional 
information on selected examples of lipid solutions, suspensions, emulsions and solid 
dispersions can be found in a review by Humberstone and Charman (1997), SEDDS 
by Pouton (1997) and Gershanik and Benita (2000), and solid lipid nanoparticles by 
Muller et al. (2000). 
Despite the numerous studies shown in these tables, only a relatively few commercial 
formulations of lipid based systems are available on the market. These are 
cyclosporine (Sandimmune™ and NeoraFM, Novartis), saquinavir (Fortovase™, 
7 
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Roche), ritonovir (Norvir™, Abbott) and fat-soluble vitamins. Possible reasons for the 
rarity of commercially available lipid-based products are the physical complexity of 
lipids, reliability of supply (quality), lack of knowledge of mechanisms of drug 
absorption and fate of the lipid in the gastrointestinal tract. An additional factor may 
be the limited solubility of pharmaceutical compounds in lipid solvents. Overall, the 
lack of mechanistic understanding of the role oflipids in drug absorption is a key 
reason for their underutilization for formulation development. 
4. FORMULATION CONSIDERATIONS OF LIPID BASED SYSTEMS 
4.1. Selection of lipid vehicles 
For a lipid to be used in a drug delivery system it must be safe and ,therefore, the first 
requirement for these excipients is to be classified as GRAS (generally recognized as 
safe) materials. The majority of lipids used in marketed products do fulfill this 
requirement. In lipid formulation development, potential toxicity of any surfactants 
need should be considered carefully. This evaluation includes not only the type of the 
surfactant but also the concentration/dose (Swenson et al., 1994). 
Drug solubility in the lipid is an important factor in the selection of the lipid as a 
vehicle. Determination of solubility of drugs in lipids is a major challenge since 
solubility of drugs in lipid based system is a poorly understood concept. There is no 
published systematic study to show a relationship between solubility in lipid and 
physicochemical properties of the drug such as molecular weight, logP and melting 
point. It has been shown that in the case of an investigational anti-HIV agent solubility 
8 
increases as ester bond concentration of lipid increases (Anderson and Marra, 1999). 
Determining the solubility parameter of a lipid vehicle and thereby quantifying its 
cohesive energy can offer a solution for screening of lipid candidates. Calculated 
solubility parameters can be used for this purpose. The closer the solubility parameter 
of a drug to that of a lipid vehicle, the more soluble would be that drug in such a 
vehicle (Dumanli et al., 2000). 
The formulation scientist should also take into account the fact that the solubility of a 
drug may change due to the changes in the vehicle during the products shelf life. For 
example, partitioning of water from the gelatin capsule shell into the lipid can have a 
significant effect on the solubility of the drug. Therefore, the hygroscopicity of the 
lipid used in such formulation should be carefully evaluated (Fig. I). Furthermore, the 
dissolved drug in a solid lipid may precipitate out during processing when the 
formulation is cooled down to room temperature. The solubility of a drug in solid 
lipids should be significantly higher than final concentration in the formulation. 
Solubility should be determined under extreme conditions that the product would be 
subjected to during processing, manufacture and its shelf life. It should also be kept in 
mind that the release of a drug from the vehicle is the inverse function of its solubility 
in the lipid solvent. Therefore, chemical potential (concentration/solubility) and 
partitioning of the drug from lipid to immediate aqueous environment should be 
considered in addition to drug solubility and concentration (Armstrong and James, 
1980). 
9 
( To optimize both the lipid solubility and release of the drug, co-solvent and 
surfactant/s may be added to the formulation. Cremophor EL a commonly used 
surfactant has increased the solubility oflipophilic drugs, griseofulvin and nifedipine, 
Table 10. The ratio of co-solvents should be optimized to avoid potential precipitation 
of the drug following aqueous dilution. Lipid vehicle, surfactant, co-solvent and drug 
combinations can be evaluated upon aqueous dilution using phase diagrams (Shah et 
al., 1994; Constantinides, 1995 and Kim et al. 2000). 
4. 2. Effect of HLB 
As mentioned above, there is no distinct difference between a surfactant and a lipid 
that is surface active. In order to achieve good dispersibility and absorption, it may be 
necessary to use both surfactant/sand lipid vehicle/sin formulations such as SEDDS, 
emulsions and microemulsions. HLB plays an important role in the selection of lipid 
vehicles in these types of lipid formulations. Even though most of the lipids have no 
surface active properties, some of them like medium chain mono-glycerides and PEG 
esters exhibit surfactant properties. These can have HLB values up to 14, (Table lF). 
HLB of a lipid vehicle/surfactant can affect the solubility of a drug. For example, as 
the HLB increases, the solubility of griseofulvin increases (Fig. 2) (Dumanli et al., 
2000). The effect of HLB on drug release rate from a lipid based formulation is shown 
in Fig.3. HLB value of a lipid vehicle also significantly influences the self-
emulsification and dissolution properties of a SEDDS formulation (Shah et al., 1994, 
Kim et al., 2000 and Nazzal et al., 2002). 
10 
( 4. 3. Drug Loading 
The factors determining the loading capacity of a drug in solid lipid nanoparticles 
include as (I) drug solubility in molten lipid, (II) miscibility of molten drug in a lipid 
melt, (III) chemical and physical structure of solid lipid matrix and (IV) polymorphic 
state of lipid material (Muller et al. 2000). 
It is not advisable to use a saturated solution in solid lipids because some of the drug 
may precipitate out at ambient temperature causing structural variations within the 
system. Resulting crystalliz.ation may lower the bioavailability. 
In lipid formulations with high drug concentration, determination of the saturation 
point of the drug becomes a critical factor in the formulation design. If the drug 
precipitates out in gastrointestinal tract, its bioavailability may be reduced. However, 
the use of appropriate lipid vehicle at the optimum level can overcome this problem as 
it has been shown in the case of lipid formulation ofDMP 323, a poorly soluble HIV 
protease inhibitor. A formulation containing Gelucire 44/14 (a mixture of glycerides 
and PEG esters) increased DMP 323 aqueous solubility and dissolution rate, and 
enhanced the bioavailability at high doses (August et al. , 1997). 
Drug loading can also affect physiochemical properties of the formulation. For 
example, increasing concentration of L-365,260, a poorly soluble benzodiazepine 
derivative, caused changes in droplet size of emulsions prepared with Labrafil M 
2125CS (Craig et al. , 1993). 
11 
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A poorly soluble drug substance dissolved in MCM can significantly affect 
rheological properties and particle size of the formulation as a function of its 
concentration (Fig. 4). Change in slope of zero shear viscosity vs. concentration shows 
that the lipid solvent cannot accommodate too many solute molecules so that the drug 
reaches the saturation point where further addition of the drug may cause 
entanglement of the molecule (Dumanli and Kislalioglu, 1999). 
Concentration and surface active properties of a drug in a lipid vehicle can modify the 
phase transition of a lipid. However, such an effect is dependent on the properties of 
the drug. For example, griseofulvin facilitates liquid crystal formation in glyceryl 
mono-oleate (GMO) at saturated concentration whereas nifedipine does not have the 
same influence. At the physiological temperature, GMO forms a cubic phase via 
reverse micellar transformation which is concentration specific. Above a certain 
concentration, lipophilic drugs such as ibuprofen and propranolol transformed the 
cubic phase into an inverted hexagonal phase where the system becomes less viscous 
resulting in modification of the release properties (Chang and Bodmeier, 1997). As the 
water content of cubic phase is increased, the system may become more viscous 
(Engstrom, 1990) and may sustain the release of the drug. On the other hand this 
phenomenon may enhance the stability. Enhanced stability of cefazolin and 
cefuroxime in glyceryl mono-oleate cubic phase gels showed its potential as a 
chemical stability enhancer, protecting the antibiotics from P-hydrolysis and oxidation 
as a result ofreduced motility of water, in the gel (Sadhale and Shah, 1998). 
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4. 4. Manufacturing and Stability Considerations 
Most of the lipid-based formulations especially the ones that contain semi-solid/solid 
lipids involve the application of heat during their preparation. Duration of heat 
application, temperature and cooling rate can have a significant effect on the quality 
and stability of the final product. Scale-up processes of these formulations are also 
challenging because duration of heat application and cooling rate can change with 
increased scale. Therefore, optimal process should be always considered during 
development to assure scale-up certainty and robustness. DSC and viscosity 
measurements can be useful tools to monitor the effect of temperature, holding time 
and cooling rate. Many lipids may exhibit polymorphic transitions upon storage or 
during processing. It has been shown that cooling rate can affect endotherms of 
Gelucires upon aging (Sutananta et al., 1994). 
Most of liquid and semi-solid lipids contain unsaturated bond that photo- and auto-
oxidize. Peroxide formation with oxidation can damage the drug and induce toxicity. 
Lipid peroxides may also form due to autoxidation, which increases with unsaturation 
level. Hydrolysis of the lipid may be accelerated due to the pH of the solution or from 
processing energy such as ultrasonic radiation (Weiner, 2002). Including an anti-
oxidant (i.e. cx:-tocopherol, propyl gallate, ascorbate or BHT) can be necessary in lipid-
based formulation. Hygroscopicity of the vehicles (Fig. 1) is also important for 
stability of gelatin capsules. Water migration into capsule fill can cause cracking of 
the capsule shell. 
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5. EFFECTS OF LIPIDS DURING ABSORPTION OF POORLY SOLUBLE 
DRUGS 
5.1 Lipolysis and systemic absorption 
Understanding of lipid digestion process is important in design of lipid-based 
formulations. Digestion process involves 3 basic steps (Fig. 5): (I) dispersion of lipid 
into gastric media and emulsification by gastric motility, (II) enzymatic hydrolysis of 
tri-glycerides into mono-glyceride and fatty acids, (III) the formation of mixed 
micelles with hydrolysis products and bile salts and ultimately absorption through the 
intestinal wall (Carey et al., 1983). The lipid digestion process has been exclusively 
described for tri-glycerides. However, there is little information on the fate in Gastro-
intestinal (GI) lumen of lipids such as propylene glycol esters of fatty acids, 
polyglycerol and polyethylene glycol esters. 
Micelle formation of lipolytic products with bile salts is the crucial step that enhances 
drug solubilization and absorption. The total solubility of certain drugs is proportional 
to taurocholate concentration, a major bile salt in the small intestine. A linear 
relationship was shown between solubilization and logP of steroids, cyclosporine A, 
griseofulvin (Mithani et al., 1996). A detailed discussion of the lipid digestion process 
and its impact on drug absorption from the gastro-intestinal tract can be found in other 
reviews (Eldem and Speiser, 1989; Embleton and Pouton, 1997; Humberstone and 
Charman, 1997; MacGregor et al., 1997). 
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( The nature of lipids used in the formulation can affect the lipolysis process. The in 
vitro lipolysis process can be used to elucidate the effect of lipids on lipolysis. The 
details of the process are described in section 6.2.2. 
The nature of oil as an influencing factor on absorption ofSEDDS has been discussed 
(Craig et al. 2000; Gershanik and Benita 2000). The fatty acid chain length directly 
influences lipolysis. The long-chain fatty acids are more inhibitory than the medium-
chain ones (Bernback et al., 1987; Hutchison, 1994; Zangenberg et al., 1998; Olbrich 
and Muller, 1999; Lacy et al., 2000). The results in Fig.6 show that the shorter chain 
length allows more rapid lipolysis among tributyrine, MCT (Miglyol 812) and LCT 
(soybean oil) (Hutchison, 1994). Lipase enzyme is active only at interface. The greater 
the interface the higher the lipase activity is. Therefore, the extent of lipolysis is very 
low for triacetin, this is because it is miscible with aqueous medium so that no 
oil/water interface can be formed. The comparison study of in vitro lipolysis between 
medium chain and long chain triglycerides quantified by titrimetric, highpreformance 
thin-layer chromatography (HPTLC) and ultracentrifugational techniques (Sek et al., 
2002) showed that the rate and extent of digestion of the medium chain triglycerides 
was greater than long chain lipids and independent of bile salt concentration. 
The surfactants have also important effect on lipolysis. Hydrophilic surfactants such as 
Brij 96 (polyoxyethylene 10 oleoyl ether), Tween 80 (polysorbate 80) and Cremophor 
RH40 (polyoxyl 40 hydrogenated castor oil) that have HLB value more than 10 
inhibits lipolysis while lipophilic ones such as Span 20 (sorbitan mono-laureate) and 
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Crill 4 (sorbitan mono-oleate) that have HLB less than 10 do not. This inhibitory 
effect with hydrophilic surfactants can be minimized by adding lipophilic co-
surfactants like medium chain mono-/di-glycerides to the formulation of interest. In a 
recent US Patent (Lacy et al., 2000), it was found that transesterification products of 
polyoxyethylene glycol with glycerol esters of capric and caprylic acids, do not inhibit 
the in vivo lipolysis of digestible oils. Labrasol (glyceryl caprylate/caprate and PEG 
caprylate/caprate) and Softigen 767 (PEG-6 caprylic/capric glyceride) with HLB 
values of 14 were given as examples hydrophilic surfactants that do not have 
inhibitory effect on lipolysis. 
A rapidly digested lipid would promote maximum drug absorption (Hutchison, 1994). 
For example, when MCT and LCT have been compared for the absorption of vitamin 
E, MCT enhanced intestinal absorption of vitamin E (Gallo-Torres et al., 1978). 
However, this effect can not be generalized. CyclosporineA absorption, in contrast to 
vitamin E, was higher in LCT than in MCT (Behrens et al., 1996; Renner et al. l 988a, 
b ). This difference was interpreted as the result of formation of mixed micelles which 
occurs during the digestion. 
Fluidity and volume of the lipid can affect the gastric retention as it was shown in the 
absorption ofSL-512, an anti-inflammatory agent, (Yamahira et al., 1978) and 
Phenytoin (Shinkuma et al., 1985). Medium chain tri-glyceride, medium chain mono-
glyceride, com oil and N-methylbenzyllinoleamide (MBLA) has been investigated as 
model lipid vehicles. The solubility of SL-512 was found to be 0.5, 4.2, 0.3 and 2.2% 
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(w/v) in each vehicle, respectively. Even though, MCM provided the highest solubility 
ofSL-512, it has not provided the highest serum level and gastric emptying time. It 
was concluded that serum level and gastric emptying time of SL-512 was correlated 
with fluidity of the lipids. 
Gastric emptying was also affected by the chain length of fatty acids (Hunt and Knox, 
1968). Fatty acids with 12-18 carbon atoms slowed down gastric emptying more than 
those with up to 10 carbon atoms. C14 (myristate) was the most effective one. 
The effect of chain length of fatty acid of the lipid vehicle on formulation design and 
the bioavailability ofHalofantrine (Hf) has been stuided (Khoo et al., 1998). The 
solubility of Hf was enhanced by increasing the proportion of Captex (MCT) for the 
medium-chain glyceride formulations based on Captex/Capmul (MCM) of 
combinations. However, this approach led to less efficient emulsification. A 2: 1 (w/w) 
ratio of Captex to Capmul provided a good balance between drug loading and efficient 
emulsification. Hf was less soluble in long-chain glycerides compared to the medium 
chain ones. Better emulsification was obtained with the formulations that contained 
medium-chain glycerides. The authors observed a trend towards higher bioavailability 
of the drug with the long-chain tri-glyceride formulations compared with medium 
chain glyceride formulations in the beagle dogs. Such anomalous findings apparently 
based on differences in intra-luminal processing of the medium- and long-chain 
glycerides where the bile salts and the formation of mixed micelles can influence 
absorption. 
17 
Lipid digestion products pass across an unstirred water layer (UWL) in the small 
intestine. Within the UWL an acidic microclimate aids micellar dissociation so that 
monomers pass passively across the brush-border membrane. For long-chain fatty 
acids passage across the unstirred water layer is rate limiting, whereas passage of 
short- and medium-chain fatty acids is limited by the brush-border membrane 
(Thomson et al., 1993). 
5.2. Lymphatic absorption 
Once the lipolysis products, fatty acids and mono-glycerides, are taken up by 
enterocytes, a re-synthesis of the fatty acids and monoglycerides takes place in the 
endoplasmic reticulum Together with cholesterol, phospholipid and proteins, 
lipoproteins are synthesized. Lipoproteins are characterized as high density 
lipoproteins (HDL), low density lipoproteins (LDL), very low density lipoproteins 
(VLDL) and chylomicrons. Among all these, chylomicrons are the most abundant in 
the intestine cells. They contain the largest amount of tri-glycerides and they are the 
largest in size. Since they cannot be taken up by the blood capillaries because of their 
size, they enter the lymph capillaries (Tso, 1985; Nijs, 1987; Porter and Charman, 
1997). Absorption of a drug through lymphatic system escapes first-pass effect. 
In order to incorporate a drug in the tri-glyceride core of the chylomicrons, the drug 
must be lipophilic. Probucol, lipophilic vitamins and halofantrine are the most 
commonly used model drugs to investigate lymphatic absorption. A lipid used in 
lymphatic delivery is important to determine the extent of lymphatic drug transport. 
The type of lipid, their degree of saturation, chain length and physical state play an 
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( important role in lymphatic transport of drugs. LCT lipids are more favorable for the 
lymphatic absorption than MCT. Fatty acids containing 14 or more carbon atoms are 
considered to be taken up in the lymph, and those containing 8-12 carbon atoms enter 
the systemic circulation through the portal vein (Armstrong and James, 1980). 
The effect of different oils on the absorption of probucol has been studied in rat (Palin 
et al., 1984). The plasma concentration ofprobucol was determined following its 
administration in arachis oil (LCT), Miglyol 812 (MCT) and liquid paraffm. The total 
absorption of the drug from lymphatic and portal system was significantly greater for 
arachis oil formulation than with the other two aforementioned vehicles. The literature 
also cites the reverse effect: The lymphatic and portal transport ofretinol (vitamin A) 
in unanesthetized rats (Hollander, 1980) demonstrated that addition of short-chain 
fatty acids to the infusate did not change the appearance rate of vitamin A in the bile 
or lymph. Lymphatic uptake rate of vitamin A peaked following the addition of 
medium chain fatty acids to the infusate. Addition of long-chain unsaturated fatty 
acids, oleic, linoleic and arachidonic to the infusate inhibited the lymphatic appearance 
of retinol as the chain length and degree ofunsaturation increased. The absorption rate 
ofretinol in the bile was increased significantly when long-chain polyunsaturated fatty 
acids, linoleic and arachidonic acids, were added to the infusate. This indicated that 
polyunsaturated fatty acids also shifted the exit of vitamin A from the lymphatic to the 
portal circulation. The preferential transport of the polyunsaturated fatty acids into the 
portal circulation may also shift the transport of vitamin A into the portal circulation 
by a co-transport mechanism. 
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( In another study with rats, three retinoids, namely isotretinoin, etretinate and 
temarotene, have been used to investigate the effects of solubility and lipophilicity on 
lymphatic uptake after oral administration in each of three oily vehicles, cottonseed 
oil, Miglyol 812 and linoleic acid (Nankervis et al., 1996). Lipid solubility increased 
with increasing partition coefficient of the retinoid. However, the rank order of 
increasing lymphatic uptake from each of three oils shows an inverse relationship with 
solubility of the retinoid in each oil. The reason was explained as follows; the retinoid 
is likely to escape from the dosing vehicle before passing across the diffusional barrier 
of the unstirred water layer in the gut. It is related to the solubility of the retinoid in the 
oil. The easier the diffusion of a drug into the intestine, the more thermodynamically 
favorable it will be for the retinoid to partition out of the oil. 
The animal model used is important in studies related to lymphatic absorption. Rat is a 
commonly used animal model to investigate lymphatic absorption of drugs. The 
physiological state of the animal is also important. The effect of type of lipid and 
formulation on lymphatic transport ofHalofantrine (Hf) has been studied in the 
conscious and the triple-cannulated anesthetized rat model (Porter et al. 1996a,b). It 
was found that the lymphatic transport ofH£ in conscious rat was independent of the 
type of lipid (triglyceride or fatty acid) and the type of formulation (micellar or regular 
solution). On the other hand, the lymphatic transport of Hf in anesthetized rat was 
dependent on the type of formulation (micellar, emulsion and solution). It was 
proposed that the lipid vehicle effects in anesthetized rat model reflected the lack of 
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gastric processing by preduodenal lipase and the shear action of the stomach that 
presents in the conscious rat model. 
The degree of unsaturation of lipid was also reported as a factor on the absorption of 
drug molecules (Craig et al. 2000). The effect of unsaturation on intestinal lymphatic 
drug absorption has been investigated. The lipoprotein fractions were monitored in 
mesenteric lymph following intraduodenal administration of arachis oil and fatty acids 
such as oleic, linoleic and linolenic to rats. It was shown that the greater the degree of 
unsaturation of the fatty acid, the more rapid the onset of chylomicron synthesis as 
indicated by more lymphatic absorption of the fatty acid (Renner et al., 1986; Cheema 
et al., 1987). However, absorption of halofantrine was largely independent on 
triglyceride unsaturation in a conscious rats (Holm et al., 2001 ). 
Lymphatic uptake was also affected by isomers oflipid used. The effect of elaidic (9-
cis) and oleic acids (9-trans) on lymphatic uptake studied showed that oleic acid 
exhibited higher lymphatic recovery rate compared to elaidic acid (Bernard et al. , 
1987). 
6. CHARACTERIZATION OF LIPID BASED FORMULATIONS 
Lipids enhance bioavailability for poorly soluble drugs. However, they are challenging 
to work with because of their physical complexity. It is imperative to use a technique 
that does not alter any physico-chemical properties of a lipid-based system. Methods 
used for characterization of SEDDS and SLN were summarized by Gershanik and 
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( Benita (2000) and Muller et al. (2000), respectively. In this review, more detailed 
techniques are cited from the literature as well as from our experience for lipid based 
delivery systems. 
6.1. Formulation and Stability Evaluations: 
Thermal and particle size analysis are the common methods that can be used to 
evaluate formulation factors such as HLB, concentration of the components and 
processing conditions and stability. 
6.1.1. Thermal Analysis: 
Differential Scanning Calorimeter (DSC) is the most commonly used thermal analysis 
technique for characterization of lipid based systems. Some of the lipid vehicles are 
solid or semi-solid, therefore formulations containing such vehicles are processed at 
temperatures higher than room temperature. Therefore, it is important to characterize 
the system with thermal analysis before the formulation process. 
DSC analysis will be useful to determine possible interaction between drug and lipid 
vehicle especially in solid dispersions. It can be helpful to construct a phase diagram 
of the drug of interest versus temperature. Solid dispersions ofUC-781, an antiviral 
agent, with Gelucire 44/14 and PEG 6000 have been characterized using DSC. 
Melting points peaks were used to construct the phase diagram for solid dispersions. 
Based on these diagrams, no eutectic mixtures were observed. Phase diagrams of solid 
dispersions and those of physical mixtures were similar suggesting that there was no 
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( significant chemical change or interaction between the drug and PEG 6000 or Gelucire 
44114. It was also showed that based on DSC data, the drug can be dissolved up to a 
concentration of25% (w/w) in the liquid phase in PEG 6000 and Gelucire 44114 
(Damian et al., 2000). 
DSC can be a useful tool in determination of stability oflipid based systems. The 
thermal behavior of stored different types Gelucires has been studied using DSC to 
examine the relationship between preparation condition and stability (Sutananta et al., 
1994). Based on DSC results, it was concluded that the thermal traces observed during 
storage are associated with the segregation or recombination of the Gelucire 
components into different microscopic regions within the sample, rather than 
polymorphic changes. They also conducted tensile strength measurements indicated 
that the strength of Gelucires changed during storage. Modulated DSC has been 
utilized in softgel capsules to screen the variables such as temperature and humidity 
influencing the hardness of gelatin capsules (Nazzal and Wang, 2001). The gelling 
mechanism that occurred in solid lipid nanoparticles that contains Compritol was 
investigated using DSC (Freitas and Muller, 1999). The results showed that the 
crystallization occur during gelation. However, if the lipid based system is liquid, this 
kind of stability problem may not be detected by DSC (unpublished data). Therefore, 
it can be said that DSC analysis is more useful for solid based lipid systems. 
6.1.2. Particle size analysis: 
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( Most lipids are either in emulsion/microemulsion form or they can form an emulsion 
upon mixing with gastric fluid (self-emulsifying systems). Droplet or particle size will 
influence performance of the ultimate dosage form. Therefore, particle size analysis is 
an important analytical tool in characterization of lipid based delivery system. There 
are number of techniques which are available to measure the particle size. These 
include optical microscopy, scattering methods such as light scattering and photon 
correlation spectroscopy and electron microscopy. Scattering methods are mostly 
commonly used since they cover a wide range particle size (from 2nm to 2 mm). 
Particle size measurements provide a quick assessment in comparison of emulsion 
systems. For example, the efficiency of self-emulsification by measuring the rate of 
emulsification has been studied by monitoring the relative intensity of light scattered 
by dispersion and particle size distribution of resulted emulsion using light microscopy 
and a Coulter Nano-Sizer (Pouton, 1985a). The mixture ofMiglyol 812 (medium 
chain tri-glyceride) or Miglyol 840 (propylene glycol ester of caprylic/capric acid) 
with the surfactant Tween 85 (polysorbate 85) provided more efficient self-
emulsification system than the mixture liquid paraffin or oleic acid with the surfactant 
Tween 85. It was concluded that the Coulter Nano-Sizer provided a quick, non-
invasive technique for comparing the mean particle sizes of resultant emulsions but 
was inappropriate for sizing all self-emulsifying systems. It was shown that the 
determination of particle size with light scattering is more important than comparison 
of emulsification rate. Light scattering has been used to measure the emulsification 
rate to explain the mechanism of the spontaneity of self-emulsifiable oils. The 
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( mechanism was explained by liquid crystal formation and it was concluded that 
spontaneity was dependent on the nature of the material used in the system (Groves 
and Mustafa, 1974). The mechanism of action for self-emulsified systems consisting 
ofTagat TO (ethoxylated glycerol tri-oleate) and Miglyol 812 (medium chain 
triglyceride) has been also studied using Low Angle Laser Light Diffraction for the 
emulsions with droplet distribution above 1 µm (Wakerly et al., 1986). Quasi-elastic 
light scattering was used for investigations of submicron dispersions. Ternary phase 
studies showed a specific region of lamellar liquid crystal dispersed in the isotropic 
phase of solubilized water. 
The particle size measurements can be useful to characterize the factors such as HLB 
of surfactant, type and concentration of co-surfactants affecting the efficacy of self-
emulsifying oral delivery system. Such study has been conducted using self-
emulsifying formulations containing surfactants (Spans and Tweens) with different 
HLB values (4.3 to 16.7), co-surfactants (mono-glycerides) with varying fatty acid 
chain length (Cs to C1s) and vegetable oils (peanut, soybean and saffiower oil) with 
different fatty acid composition (Cs to C1s ). The system was characterized using 
dissolution test and particle size measurements (Bachynsky et al.,1997). It was 
concluded that a surfactant with an HLB in the range of 11-15 at 5% concentration and 
a co-emulsifier consisting of a monoglyceride of caprylic/capric acids at 17% 
concentration were most effective in a formulation having good self-emulsifying 
properties in terms of particle size and satisfactory dissolution characteristics of an 
aratinoid model drug used. 
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( One should be aware of that using laser diffraction requires dilution of the sample that 
may alter the properties of self-emulsifying systems. Therefore, when the particle size 
of the sample is above 1000 nm, which is the upper limit of dynamic light scattering, 
electron microscopy may be used. 
6. 1. 3. Other methods 
X-Ray diffraction can be used to monitor any polymorphic changes and to detect 
possible lipid-vehicle interactions along with FT-IR (Tandon et al., 2001). Low 
frequency dielectric spectroscopy (LFDS) has been used to elucidate the mechanism 
of self-emulsification. It was shown that self-emulsification with Imwitor 742 or 
Labrafil M2125 CS and Tween 80 occurs via liquid crystal formation depending on 
surfactant/oil ratio. It was also shown that LFDS is a useful technique to examine the 
individual components in order to investigate the effects of drug inclusion. Surface 
tension and particle size measurements were also conducted in order to determine the 
effect of drug concentration (Craig et al., 1993a and b, 1995). Refractive index, 
conductance and density measurements were conducted to compare the water-in-oil 
microemulsions containing long- versus medium chain glycerides (Constantinides and 
Scalart, 1997). Rheological investigations and NMR can be used to investigate the 
effect of drug loading in MCM (Dumanli et al., 1999). In this study it has been shown 
that beyond a certain concentration, the solution reaches a saturation level causing a 
change in the slope of concentration vs. zero-shear viscosity and particle size (Fig 4). 
The effect of drug loading has been further investigated with NMR showing that as the 
26 
concentration of the drug in MCM increased, the line-widths of drug broadened while 
line-widths of MCM remained same. 
Zeta potential measurements can help to evaluate physical stability of dispersed lipid 
based systems and charged lipid-based formulations (Washington, 1996; Gershanik 
and Benita, 2000). Freitas and Muller (1998) studied the gelation mechanisms seen in 
aqueous dispersions of solid lipid nanoparticles consisting of 10% Compritol and 
1.2% Pluronic F68 by measuring zeta potential of the system. The possible 
mechanisms of gel formation are explained as the structural changes of the lipid phase 
leading to zeta potential reduction and particle growth. Recently, positively charged 
self-emulsifying formulations were developed by Gershanik et al. (1996 and 1998) to 
enhance the interaction with mucosal surface and increase cellular uptake. Zeta 
potential measurements were conducted to characterize such systems, to investigate 
the effect of progesterone incorporation on the charge of the formulation and to show 
that the enhanced electrostatic interactions of positively charged droplets with rat 
intestinal mucosa} surface are responsible for the uptake of cyclosporine A. 
6.2. In vitro/in vivo correlation (IVIVC) 
6. 2.1 Dissolution studies 
Dissolution testing for poorly soluble drugs requires different media than those 
normally used for water-soluble compounds. The incorporation of surfactant into 
dissolution media was found useful (Serajuddin, 1988; Roman, 1999; Dressman and 
Reppas, 2000). The dissolution ofUC-781 , an inhibitor of HIV-1 replication and a 
poorly soluble drug, has been carried out in aqueous polysorbate 80 solutions (Damian 
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( et al., 2000). The dissolution of physical mixtures and solid dispersions of the drug 
compared with PEG 6000 and Gelucire 44/14 showed that the drug release from 
Gelucire 44/14 was higher than from physical mixture and PEG 6000. It has been also 
shown that the micelle is sensitive to impurities and electrolytes influencing size, 
loading capacity, solubility and dissolution rate (Wasan, 2001). The type of surfactant 
used in dissolution media is important since it may interact with the capsule shells as 
in the case of sodium lauryl sulfate (SLS), an anionic surfactant that may interact with 
cationic charges of gelatin at gastric pH (Pillay and Fassihi, 1999). These interactions 
may retard the disintegration of the shell. Therefore, two-phase dissolution test method 
has been proposed for the poorly soluble compounds by Grundy et al. (1997a, b). The 
test system was used as modification of the USP XXII Apparatus 2. The important 
feature of this system is containing lower phase that has dissolution medium of750 
mL SIF and upper phase that has dissolution medium of250 mL n-octanol. Improved 
in vivo-in vitro correlation was demonstrated with two phase dissolution test by 
employing Nifedipine gastrointestinal therapeutic system (GITS). The test was used 
for dissolution studies oflipid-filled capsules employing Nifedipine as a model drug 
(Pillay and Fassihi, 1999). 
Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after 
oral administration by RRSBW distribution, known as the Weibull distribution, 
showed that prediction of plasma profile was possible in seven out of eleven classes 
(Nicolaides et al., 2001). In this study, it has been also shown that the plasma profile 
of a lipophilic drug can be predicted with appropriate in vitro dissolution data, 
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provided that the absolute bioavailability of the drug is known and the drug has 
dissolution limited absorption. 
6. 2. 2. In vitro lipolysis 
A physiologically representative medium should be used to establish in vitro lipolysis. 
For this purpose, the media can be simulated intestinal fluid containing 50 mM Tris-
maleate buffer (pH=6.5), 5m.M CaCl.2H20, 150 mM NaCl, 8 mM sodium 
taurocholate and 1.5 mM lecithin. Lipase solution should be added according to 
required enzyme activity (20 TBUs per mL of lipase-colipase is recommended). 
Lipolysis starts when the enzyme solution is added to tri-glyceride emulsion. The 
reaction can be followed by monitoring fatty acid generation via continued titration 
with pH-stat. (Hutchison, 1994; Carriere et al., 1997; MacGregor et al., 1997; 
Zangenberg et al., 2001 ). Attention should be given to the surfactant that may be 
present in tri-glyceride emulsion because most of the surfactants used in lipid 
formulation inhibit lipolysis. There are not many published studies that correlate in 
vitro lipolysis and in vivo results. Only preliminary results were given for progesterone 
with good in vivo correlation (MacGregor et al., 1997) whereas no IVIVC was 
established for cyclosporine. Olive oil as LCT and Miglyol 812 as MCT have been 
compared for cyclosporine intestinal absorption both in vitro and in vivo (Reymond et 
al., 1988a, b). An in vitro lipid digestion method established was used to compare 
LCT and MCT in terms of the drug partitioning into aqueous phase. It was 
demonstrated that lipid digestion promotes the partition of the drug in the aqueous 
phase for MCT, whereas for olive oil presence of lipolysis products in the aqueous 
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( phase after digestion decreases the distribution of Cyclosporine into this phase. 
However, their in vivo results showed that drug permeation is higher with LCT. 
Digested vehicles promoted the absorption compared to the non-digested ones. It was 
concluded that in vitro phase quantification could not simulate in vivo absorption 
events. 
6.3. Absorption mechanisms 
Increased absorption mechanisms with lipids involve increasing drug 
solubility/dissolution, changing gastric and intestinal transit time, stimulation of bile 
flow and increased intestinal permeation (Muranishi, S., 1985; Aungst et al., 1993, 
1996). Reduced particle/droplet size can be another reason that lipid-based 
formulation can provide increased absorption. These mechanisms can be elucidated 
with measuring dissolution test and particle size of the formulation, using cell 
monolayers and imaging techniques. Zeta potential measurements can also be useful 
to study the mechanism of charged lipid based systems (Gershanik et al, 1998). 
Particle size measurements can be used to show the mechanism of increased 
bioavailability of certain drugs. For example, enhanced the bioavailability of poorly 
soluble Cyclosporine A has been studied in o/w microemulsions consists of 
capric/caprylic triglyceride as an oil(Captex 355), polyoxyethylated castor oil 
(Cremophor EL™) as a surfactant, TranscutolrM as co-surfactant and saline (Gao et al., 
1998). It was concluded that the enhanced bioavailability of Cyclosporine A loaded in 
this microemulsion system was due to the reduced droplet size of microemulsion 
systems. 
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( Physicochemical interactions between the self-emulsifying system and intestinal 
mucosa can also affect drug absorption. The interaction of a self-emulsifying lipid 
drug delivery system with the everted rat intestinal mucosa has been demonstrated as a 
function of droplet size and surface charge (Gershanik et al., 1998). A positively and a 
negatively charged self-emulsifying system was prepared with ethyl-oleate and 
oleylamine using Cyclosporine A as a lipophilic model drug. Transmission electron 
microscopy has been used to measure the particle size of the self-emulsifying systems. 
They found that the enhanced electrostatic interactions of positively charged droplets 
with the mucosa} surface are mostly responsible for the preferential uptake of 
Cyclosporine A from the positively charged droplets as compared to negatively 
charged droplets. Positively charged self-emulsifying oil formulation containing 
Tween 80, benzyl alcohoL ethyl oleate and oleylamine also elicited the highest and 
most satisfactory absorption profile for progesterone (Gershanik and Benita, 1996). 
6. 3.1. Imaging techniques 
Imaging techniques such as scintigraphy, ultrasound and magnetic resonance imaging 
can be used to get detailed visualization of transit absorption oflipids in the body. The 
effect of oleic acid on human ileal break was determined by measuring the transit of 
radio-labeled tablets by gamma scintigraphy in volunteers (Dobson et al., 1999). It 
was shown that oleic acid activated the ilea} brake that slowed the transit of tablets 
through small intestine. Readers can refer to a review by Wilson et al. (1997) for 
more details about imaging techniques. 
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6. 3. 2. The use of cell monolayers 
The Caco-2 cell, derived from a human colorectal carcinoma, has been used 
extensively to study the permeation of drug compounds. It especially useful to predict 
the intestinal absorption mechanisms. Mechanisms of lipid uptake and metabolism 
have been studied in the nutrition area using Caco-2 cells as a model. This information 
can be applied to study lipid based drug delivery. It has been reported that many of the 
biochemical and metabolic features of lipid processing in vivo have been shown to 
exist in Caco-2 cells (O'driscoll, 1998). These features include fatty acid uptake, 
esterification and triglyceride formation, cholesterol absorption, esterification and 
synthesis, synthesis and secretion of lipoproteins, expression of P-glycoproteins (P-
GP) and CYP3A-like cytochrome P450 activity. However, it is important to be aware 
of fact that there are also some differences such as no fatty acid binding proteins 
(F ABP) in Caco-2 cells. 
Efficacy and toxicity screening of various enhancers has been studied using Caco-2 
cell (Quan et al., 1998). The findings indicated that the effectiveness of absorption 
enhancers in the Caco-2 monolayer system was similar to an in vivo rat system. The 
Caco-2 cell model was also used to investigate the charge dependent interactions of 
positively charged SEOF with human intestinal epithelial cells (Gershanik et al., 
2000). It was shown that the positively charged emulsions affected the barrier 
properties of the cell monolayer at high concentrations and reduce the cell viability. 
However, no detectable cytotoxic effect was observed with following dilution. 
32 
( The effects ofCapmul MCM on physiological properties of rabbit ileum and distal 
colon, including active ion transport, trans-epithelial resistance and passive 
permeability have been investigated in vitro (Yeh et al., 1994). It was found that 
Capmul MCM inhibited active ion transport. 
7. CONCLUSIONS 
Lipids can play a significant role in improving absorption of poorly soluble drugs. 
Their physicochemical and physiological aspects should be well defined. 
Physicochemical aspects including characteristics of lipids and its affect on drug 
solubility and stability should be studied. In physiological aspects, understanding the 
lipid digestion process will help to design a rational lipid drug delivery systems. 
Judicial selection of lipids through knowledge of a lipid's physicochemical and 
physiological properties can overcome absorption of poorly soluble drugs. This is 
rapidly evolving area and the future of lipid drug delivery system is quite promising. 
Certainly, further research on areas like lipid digestion and absorption is desirable. 
More mechanistic studies that will include different variety of lipids are needed. The 
type of model drugs used in research purpose should be extended to be more 
representative and rational. The drug/lipid relationship should be carefully 
investigated to design a cost-effective formulation with enhanced bioavailability 
together with optimum stability and manufacturability. 
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Table 1: Examples of Commonly Used Lipids in Oral Drug Delivery 
Table lA: Examples of Fatty Acids Commonly Used in Oral Drug Delivery 
Chemical Chemical Name Examples of Trade Some Physico-chemical Properties* 
Structure Names Fonn11 MP (°C) HLB Density1 IT2 
Caprylic acid (Cs) Emery 657 (Henkel) L 16.5 - 0.8995 2.52 
Capric acid (C10) Emery 659 (Henkel) L 31.5 - NIA NIA 
Fatty Laurie acid (C12) Emery 652 (Henkel) s 43-45 - NIA NIA 
Acids Myristic Acid (C14) Emery 655 (Henkel) s 53-55 NIA NIA -
COOH 
Palmitic Acid (C16) Emersol 143 (Henkel) s 60-68 - NIA NIA 
+:> 
\0 Stearic Acid (C1s) Emersol 153 NF s 64-70 - NIA NIA 
(CH2)n 
(Henkel) 
Oleic acid (C1s:1) Crossential 0 94 L 8-10 
CH3 
(Croda) L 8-10 0.8842 10.44 
Emersol 6313 (Henkel) 
Linoleic acid (C1s:2) Crossential L98 (Croda) L -5 
Emersol 315 (Henkel) 0.8942 11.00 
Linolenic acid (C1s:J) Crossential LN75 L -11 - 0.9036 9.43 
(Croda) 
--
Table lB: Examples of Commonly Used Glyceryl Mono- And Diesters 
Chemical Chemical Name Examples of Trade Some Physico-chemical Properties* 
Structure Names Form" MP (°C) HLB Density 1 IT2 
Glyceryl Glyceryl CapmulMCMC8 Abitec) SS - 5-6 NIA NIM 
mono- monocaprylate Imwitor 308 (Sasol) s 30-34 6-7 1.0132 NIM 
di-esters Glyceryl mono/di- Imwitor 988 (Sasol) L 20-25 4 -6 0.9931 1.20 
H2C - OH caprylate 
HC - OH Mono/di-glyceride of Capmul MCM (Abitec) L 25-30 5-6 1.0010 NIM 
H2C - O COR caprylic/capric acid Imwitor742 L 25-30 5-6 
Mono- Glyceryl mono-laurate Imwitor 312 (Sasol) s 56-60 5-6 NIA NIA 
glyceride Glyceryl Preciro!ATO (Gattefosse) s 53-57 2 NIA NIA 
Vl pa Im i tosteara te 0 
H2C - OH Glyceryl mono-stearate Capmul GMS50 (Abitec) s 57-62 3-4 NIA NIA 
H C 0-COR Imwitor 191 (Sasol) s 66-71 4 NIA NIA 
H2CO - COR Glyceryl mono-oleate Peceol (Gattefosse) L - 3 0.9352 3.32 
Di glyceride Capmul GMO (Abitec) L - 3-4 0.9378 3.58 
Glyceryl Maisine (Gattefosse) L - 4 0.9385 3.87 
Glyceryl behenate Compritol 888ATO s 69-74 2 NIA NIA 
-..... 
~-
Table lC: Examples of Commonly Used Triglycerides 
Chemical Chemical Name Examples of Trade Some Physico-chemical Properties* 
Structure Names Form11 MP (°C) HLB Density 1 IT2 
Caprylic I Crodamol GTCC (Croda) L - - 0.9325 15.20 
Capric triglyceride Labrafac CC (Gattefosse) L - 1 0.9331 13.96 
Triglycerides Miglyol 810 (Sasol) L - 1.5 0.9404 12.06 
H2C- O-COR Captex 300 (Abitec) L - 1.5 0.9414 14.76 
NeobeeM5 (Stepan) - - 0.9354 15.14 
HC- 0-COR Glyceryl tricaprate Captex 1000 ( Abitec) s - 1.5 NIA NIA 
Glyceryl trimyristate Dynasan 114 (Sasol) s 55-58 I NIA NIA 
H2CO- COR 
V1 Glyceryl tripalmitate Dynasan 116 (Sasol) s 61-65 1 NIA NIA 
........ 
Glyceryl tristearate Dynasan 118 (Sasol) s 70-73 1 NIA NIA 
Glyceryl trioleate Captex GTO (Abitec) L - I 0.9056 16.87 
--
Table lD: Commonly Used Propylene Glycol Esters 
Chemical Chemical Name Examples of Trade Some Physico-chemical Properties* 
Structure Names Fonn11 MP (°C) HLB Density1 IT2 
Propylene glycol Propylene glycol Capmul PG-8 (Abitec) L - 2-3 0.9372 3.2 
esters 
monocaprylate Capryol 90 (Gattefosse) L 6 0.9360 5.9 -
Propylene glycol Captex 100 (Abitec) L - 2-3 NIA NIA 
H3C di ca prate Propyleneglycol Captex 200 (Abitec) L - 3 0.9078 11.3 
HC - 0 COR dicaprylatel 
H2C - O COR dicaprate 
Propylene glycol Lauroglycol 90 L - 5 0.9136 6.7 
monolaurate (Ga ttefosse) L 4 NIA NIA -
Capmul PG-12 (Abitec) 
Vl Propylene glycol E-32238 (Cognis) L NIA N - - NIA 
monooleate 
Propylene glycol Emery 2379-U (Cognis) L - - NIA NIA 
dioleate 
~ 
Table lE: Commonly Used Polyglycerol Esters 
Chemical Structure Chemical Name Examples of Trade Some Physico-chemical Properties* 
Names Form11 MP (°C) HLB Density 1 IT2 
Polyglyceral esters Diglyceryl mono-oleate Capral 2GO L - 0.9733 2.66 
CH2 - 0-COR (Abitec) 
Triglyceryl mono-oleate Capmul 3GO L - 6.5 0.9756 2.34 
CH - OH (Abitec) 
H2C-O Triglyceryl mono- Capmul 3GS s 6.5 NIA NIA -
CH2 (Abitec) stearate 
HC- OCOR 
Hexaglyceryl di-oleate Capra! 6G20 (Abitec) L 8.5 -
0-CH 
Hexaglyceryl di-stearate Plural Oleique L - 6 1.0211 1.59 
u. H2C VJ (Gattefosse) s 8.5 -
HC-OH 
Capra! 6G2S (Abitec) 
H2C - O-COR Decaglyceryl tetraoleate Capra! 10G40(Abitec) L - 6 NIA NIA 
Decaglyceryl decaoleate Capra I 1OG100 L - 3.5 NIA NIA 
(Abitec) 
V'I 
+>-
Table IF: Commonly Used PEG Esters 
Chemical Chemical Name Examples of Trade Names Some Physico-chemical Properties* 
Structure Form11 MP (°C) HLB Density 1 
Poly-ethyleneglycol PEG200 caprylatelcaprate E-32237 (Cognis) L - - NIA 
esters PEG200 monolaurate Emerest 2620 (Cognis) L - 9 NIA 
COR PEG200 monooleate Emerest 2624 (Cognis) L - 8 NIA 
0 (CH2 PEG400 caprylatelcaprate Softisan 767 (Sasol) L - 14 1.0651 
CH2 PEG400 monolaurate KesscoPEG400ML (Stepan) L - 13 0.0179 
O)n PEG400 dilaurate KesscoPEG400DL (Stepan) L - 10 0.9786 
H PEG400 monooleate Emerest 2646 (Cognis) L - 12 NIA 
PEG400 dioleate Kessco PEG 400 (Stepan) L - 8.5 0.9690 
PEG 1500 lauratelmyristate Gelucire 44114 (Gattefosse) SS 44 14 NIA 
PEG 1500 palmitatelstearate Gelucire 50113 (Gattefosse) SS 50 13 NIA 
*Our calculations and experimental findings 
# L: Liquid, S: Solid, SS: Semi-solid 
'Density measurements (glcm3) were done using Paar Oscillating U-Tube method at 37°C. 
2Interfacial tension (IT) (mNlm) against gastric fluid were conducted with Kruss K 12 Tensiometer using the ring method at 3 7°C, 
NIM: It could not be measured due to spontaneous emulsification NIA: Not available 
~ 
V1 
V1 
-
Table 2: Properties of Type I, II, IIIA and IIIB Lipid Formulations Based on Pou ton Classification (Redrawn with the 
permission of publisher of ref. Pouton, 1999) 
Increasing Hydrophilic Content ... 
Type I Type II Type IIIA Type IIIB 
Typical Composition 
Triglycerides or mixed glyceride 100% 40-80% 40-80% <20% 
Surfactants - 20-60% 20-40% 20-50% 
(HLB<12) (HLB>l 1) (HLB > l I) 
Hydrophilic cosolvents - - 0-40% 20-50% 
Particle size of dispersion Coarse 100-250 nm 100-250 nm 50-100 nm 
Significance of aqueous dilution Limited Solvent capacity Some loss of Significant phase 
importance unaffected solvent capacity changes & 
potential loss of 
solvent capacity 
Significance of digestibility Crucial Not crucial but Not crucial Not required 
requirement likely to occur may be inhibited Not likely 
...... 
----. 
Table 3. Lipid Systems: Solution and Suspension 
Composition of lipid Drug investigated Purpose of the study Outcome of the study Reference 
formulation used 
3% (v/v) Phenol red Phenol red To seek a relationship Fatty acids from C2 to C IO do not Hunt and 
- 0.1 N Potassium MW= 354, between the chain length of change gastric emptying time, while Knox 1968 
salts of saturated oil-soluble model fatty acids and the slowing of fatty acids with C1 2 to C1 s carbon 
fatty acids compound gastric emptying atoms delayed in gastric emptying 
(C2 - C1 s) 
- Water to make 
1000 mL 
- 0.5% (w/v) solution SL-512 To investigate the Higher viscosity and volume of Yamahira 
of drug in MCT, MW =296.5 , relationship between drug lipids ( ~ 100 µL/rat) delayed the et al. 1978 
MCMandMBLA anti-inflammatory absorption and gastric absorption of the drug due to longer 
- 0.5% suspension of agent emptying of lipid retention time of drug in the stomach 
drug in com oil formulations Vl 
0\ 
~ 
Table 3. Lipid Systems: Solution and Suspension (continued) 
Composition of lipid Drug investigated Purpose of the study Outcome of the study Reference 
formulation used 
1 % (w/v) drug solution SL-512 To investigate the absorption Serum level of the drug was found Yamahira 
m: MW =296.5, characteristics of the drug in to be much higher from MCT et al. l 979a 
- MCT anti-inflammatory rats in relation to digestibility (digestible lipid) than from MBLA 
- MBLA agent of lipids (non-digestible lipid) 
- 5% drug (as Cyclosporine A To compare the effect of Absorption of the drug was 10 times Behrens et 
solution in ethanol) MW=l202, LCT and MCT on absorption higher with LCT than with MCT. al. 
qs. to l 00% olive 
. . in conscious dogs The difference was due to the 1996 
-
1mmunosuppress1ve 
oil as LCT or formation of mixed micelles which 
Miglyol812 as occurs during digestion ofLCT but 
MCT notMCT 
V1 
-..J Unit dose consists of: Probucol To investigate the effect of Digestible oils (Arachis oil and Palin et al. 
100 mg/kg drug and 0.5 MW = 516.9, lipid vehicles on the Miglyol 812) provided higher 1983 
mL of one of hypocholesterolemic gastrointestinal absorption of plasma concentrations than Liquid 
following lipid vehicles probucol in rats paraffin. Arachis oil provided the 
- Arachis oil , highest plasma and lymph 
- Miglyol 812 concentrations 
- Liquid paraffin 
~ 
/ -
Table 3. Lipid Systems: Solution and Suspension (continued) 
Composition of lipid Drug investigated Purpose of the study Outcome of the study Reference 
formulation used 
Oleic acid - To determine the effect of The use of fatty acids with greater Cheema et 
- Linoleic acid unsaturation on lipoprotein unsaturation should be considered in al. 
- Linolenic acid fractions in the lymph lymphatic drug delivery because 1987 
- Arachis oil they increase the onset of 
chylomicron synthesis 
7.1 % Drug in: Ubidecarenone To improve the absorption of Bioavailability was same compared Pozzi et al. 
- Glyceryl MW= 863, the drug to the physical precipitate of the 1991 
monooleate used in angina drug 
pectoris 
Vl Solution of 3 retinoids Isotretinoin MW = To investigate lymphatic Lipid solubility increased as log P Nankervis 
00 (3mg/mL) in each 300, transport of three retinoids in increased but lymphatic uptake et al. 1996 
vehicle: Etretinate MW = the rat in terms of effect of decreased as the solubility increased 
- Cottonseed oil 354, lipophilicity and lipid vehicle 
- Miglyol 812 Temarotene MW = 
- Linoleic acid 304, 
used in acne 
treatment 
,-
Table 3. Lipid Systems: Solution and Suspension (continued) 
Composition of lipid Drug investigated Purpose of the study Outcome of the study Reference 
formulation used 
Unit dose contains: Halofantrine To investigate the lymphatic Lymphatic transport was evaluated Porter et al. 
- 4% (w/v) Drug MW= 500.5 , transport of Halofantrine using micellar, emulsion and 1996 a & b 
- 50µL mixture of antimalarial solution formulations. The lipid 
oleic acid and solution provided the least intestinal 
glyceryl mono- lymph and plasma uptake of the 
oleate (2: 1 w/w) drug in the triple-cannulated 
anesthetized rat model 
7.5 % (w/v) drug in Ontazolast To compare the All lipid formulations provided a 14- Hauss et al. 
Peceol MW =335, bioavailability of the drug as 19-fold increase in bioavailability 1998 
used for asthma aqueous suspension, compared to an aqueous solution. 
emulsion and SEDDS Lipid solution provided the highest 
Vl 
lymphatic absorption 
l.O Perry & 
200 mg drug with Saquinavir To compare the powder and Bioavailability of Saquinavir in lipid Noble 1998 
MCM in unit dose MW = 671, lipid formulation of the drug is 3 times higher than that of powder 
HIV protease formulation 
inhibitor 
~ 
~ 
Table 4. Lipid Systems: Micellar Solutions 
Composition of lipid Drug used Purpose of the study Outcome of the study Reference 
formulation used 
350nM retinal Retinal To seek the influence of pH, Caprylic acid provided the highest Hollander, 
- 2.5mM fatty acid (Butyric MW= bile and fatty acids on retinal lymphatic transport whereas 1980 
acid (C4),0ctanoic acid (Cs), 286.5, lymphatic and portal transport linoleic and arachidonic acids 
Oleic acid (C 1s: 1), Linoleic vitamin A provided the highest portal 
acid (C 18:2) or Arachidonic transport 
acid (C204) 
- 5-15mM Sodium taurocholate 
-
19.2mM Fatty acid (palmitic, To investigate the effect of There were no differences in the Renner et 
oleic or linoleic) saturated and unsaturated size of chylomicrons formed with al., 1986 
19.2 Monoolein lipids on the composition of saturated and unsaturated lipids 
- 20mM Taurocholate lymph tri-glycerides in rats but their clearance rates varied 
0\ 
0 
Unit dose contains: Halofantrin To investigate lymphatic Micellar solution provided higher Porter et 
- 4% (w/v) Drug e transport of Halofantrine lymph and plasma concentration al., l 996b 
- 50µL mixture of oleic acid MW= than an emulsion and a solution in 
and glyceryl monooleate (2: I 500.5, the triple-cannulated anesthetized 
w/w) anti malaria rat model 
- 4% (w/v) Tween 80 l 
- Saline to make 2.88 mL 
Table S. Lipid Systems: Emulsions and Microemulsions 
Composition of lipid Drug used Purpose of the study Outcome of the study Reference 
formulation used 
0.0005% (w/v)Vitamin E D-a-(5-Methyl- To develop MCT formulation MCT enhanced the intestinal Gallo-
- 5.7% (v/v) Trioctanoin H) tocopherol for Vitamin E and compare absorption because it increased Torres et 
(MCT) or Triolein MW =430, the bioavailability between water solubility of vitamin E al. 1969 
(LCT) vitamin E MCTandLCT and 1978 
- carbohydrate, saline and 
proteins 
1 % (w/v) micronized drug Griseofulvin To investigate absorption The bioavailability has been Carrigan 
I% (w/v) Polysorbate 60 MW = 353, characteristics of the drug increased 2.5-fold with and Bates 
40% (v/v) com oil anti fungal from o/w emulsions and emulsions compared to aqueous 1973 
water to make 100% suspensions suspension 
0\ 0.334 % (w/w) drug Danazol To compare the Emulsion formulation increased Charman 
in glyceryl mono-oleate MW = 337.5, bioavailability of danazol the bioavailability of drug 4- et al. 
emulsion steroid hormone from an emulsion and a tablet fold compare to tablets in fasted 1993 
in human in fed and fasted subjects but the differences was 
state not significant in the fed state. 
Table 5. Lipid Systems: Emulsions and Microemulsions (continued) 
Composition of lipid Drug used Purpose of the study Outcome of the study Reference 
formulation used 
- Sandimmune- Emulsion Cyclosporine A To compare the Microemulsion provided 3 Mueller, et 
form(25 , 100 mg drug in MW=l202, pharmacokinetics of a times higher absorption than the al. , 1994 
com oil , glycerol, 
. . 1mmunosuppress1 microemulsion and an emulsion and reduced the inter-
Labrafi1M2125CS and ve emulsion in human subject variability 
alcohol) 
- Neoral- Microemulsion 
form ( 15, 30, 60 mg drug 
in com oil , polyoxyl 40 
hydrogenated castor oil 
and alcohol) 
4% (w/v) Drug Halofantrine To compare lymphatic Emulsion provided higher Porter et al. 
0\ 
- 50µL mixture of oleic MW= 500.5 , transport of Halofantrine with lymphatic transport than 1996b N 
acid and glyceryl mono- antimalarial emulsion, solution and solution, lower than micellar 
oleate (2: l w/w) micelle solution 
- 0.2% (w/v) Tween 80 
- Saline to make 2.88 mL 
Microemulsion of the drug Cyclosporine A To compare bioavailability of The bioavailability of the drug Gao et al. , 
with various ratios of with MW = l202, an o/w microemulsion with in the microemulsion system 1998 
Captex355, ChremophorEL, 
. . 
marketed products, was increased 3.3 and 1.25 fold 1mmunosuppress1 
Transcutol and saline ve Sandimmun and Neoral compared to Sandimmun and 
Neoral , respectively 
------
Table 6. Lipid Systems: SEDDS/SMEDDS 
Composition of lipid Drug used Purpose of the study Outcome of the study Reference 
formulation used 
A range of Benzoic acid To investigate the inclusion Formulations containing 
concentrations of MW = 122, of a model drug on the 1.5-2% benzoic acid were Pouton, I 985b 
benzoic acid were model compound performance of SEDDS the most efficient. 
dissolved in: 
- 30% (w/w) Tween 
85 
- 70% (w/w) Miglyol 
812 
Ternary phase of: To investigate the Self-emulsification was a Wakerly et al. , 1986 
- Tagat TO, mechanism of action of result of aqueous 
ethoxylated SEDDS penetration into the liquid 
glycerol trioleate, crystal aided by mechanical 
0\ 
- Miglyol 812 dispersion \.;.) 
Neobee MS WIN 54954 To develop a SEDD SEDDS improved the Charman et al. , 1992 
TagatTO antipicornavirus formulation and compare reproducibility of the 
the bioavailability with plasma profile in terms of 
PEG solution in beagle the maximum plasma 
dogs concentration 
i'.' 
Table 6. Lipid Systems: SEDDS/SMEDDS (continued) 
Composition of lipid Drug used Purpose of the study Outcome of the study Reference 
formulation used 
2 and 6% (w/v) Drug L-365,260 Self-emulsification of the LFDS investigations show Craig et al. 1993 
- 56, 60 and 62% MW= 398, system with and without the effect of drug loading on 
(w/v) Labrafil M benzodiazepine drug was investigated individual components. 
2125 cs derivative using LFDS, surface Incorporation of drug 
- 30% (w/v) Tween tension measurements and changed the surface tension 
80 particle size analysis of the system and droplet 
- 3% (w/v) propylene size of the resulting 
glycol emulsion 
- 5% (w/v) water 
5% (w/w) Drug was Ro 15-0778 To investigate the ability of SEDDS gave 3-fold greater Shah et al., 1994 
formulated in various MW = 304, PGG with varying fatty AUC than solution, tablet 
extent of PGG, MCM, Used in acne acid and PEG chain lengths and capsule of wet-milled 
0\ PEG-25 glyceryl treatment to produce self- spray dried powder in dogs ~ 
trioleate Polysorbate80 emulsification 
and peanut oil/neobee 
oil 
0\ 
Vi 
Table 6. Lipid Systems: SEDDS/SMEDDS (continued) 
Composition of lipid 
formulation used 
10% Progesterone 
- 25% Tween 80 
I 0-50% Benzyl 
alcohol 
- 2.5-3% Oleylamine 
- to 100% Ethyl 
oleate 
7.5% (w/v) drug in 
mixture of Peceol and 
Gelucire 44/14 (either 
equal or 2:8) 
- Imwitor 742 
- Tween 80 
Drug used 
Progesterone 
MW=314, 
hormone 
Ontazolast 
MW=335, 
used for asthma 
L-683,453 
Used in benign 
prostatic hyperplasia 
Purpose of the study 
To develop and 
characterize a positively 
charged self-emulsifying 
oil formulation 
To compare the 
bioavailability of drug with 
an aqueous suspension, an 
emulsion and SEDDS 
To compare the 
bioavailability between 
aqueous suspension and 
SEDDS 
Outcome of the study 
Positively charged emulsion 
provided the highest AUC among 
a PEG 300 solution, a suspension, 
ethyl oleate and a negatively 
charged emulsion in rats. Further 
toxicity studies were 
recommended 
All lipid formulations provided 
14-19 fold increase in 
bioavailability compare to aqueous 
solution. The emulsion and 
solution provided better lymphatic 
absorption than SEDDS 
SEDDS provided 13.7% increase 
in bioavailability compared to the 
suspension 
-~, 
Reference 
Gershanik and 
Benita, 1996 
Hauss et al. 
1997 
Matuszewska et 
al. 1996 
0\ 
0\ 
Table 6. Lipid Systems: SEDDS/SMEDDS (continued) 
Composition of lipid 
formulation used 
5.66 % (w/w) drug in a 
series of self-
emulsifying systems 
containing Myvacet9-
45 , Captex200, 
LabrafacCM-10, 
Lauroglycol and 
Labrasol 
100 mg/mL 
Cyclosporine A in 
mixture of: 
- 25% (w/w) Tween 
80 
- 30% ethanol 
- 3% (w/w) 
oleylamine 
- qs.100% (w/w) 
ethyl oleate 
Drug used 
Ubidecarenone 
( CoenzymeQ 1 o) 
MW= 863, 
used in angina 
pectoris 
Cyclosporine A 
MW = 1202, 
. . immunosuppres1 ve 
Purpose of the study 
To develop and 
characterize SEDDS of Qi o 
using PGG as emulsifier 
and to evaluate 
bioavailability in dogs 
To investigate the 
interaction of positively 
charged self-emulsifying 
oil formulations with rat 
everted intestinal mucosa 
Outcome of the study 
A two-fold increase in the 
bioavailability was observed 
compare to tablet formulations 
Electrostatic interactions were 
responsible for uptake of the drug 
from the positively charged 
droplets 
Reference 
Kommuru, et al., 
2001 
Gershanik et al. , 
1998 
O"I 
-....) 
Table 7. Lipid Systems: Solid Dispersions/Solutions 
Composition of lipid 
formulation used 
15-45% drug 
55-85% one of 
the following 
vehicles: Gelucire 
44/ 14, PEG l 000, 
PEG, 1450and 
PEG 8000 
18% drug 
82% 
gelucire44/ 14 and 
PEG 400 mixture 
(6: l) 
5 % drug 
30% Gelucire 
44/14 
65% Soya lecithin 
Drug used 
REV 5901 
MW=355, 
5-lipoxygenase 
inhibitor 
REV 5901 
MW=355, 
5-lipoxygenase 
inhibitor 
Ubidecarenone 
MW= 863, 
used in angina 
pectoris 
Purpose of the study 
To investigate the effect of 
vehicle amphiphilicity on 
dissolution and 
bioavailability in dogs 
To compare the 
bioavailability from tablets 
and solid dispersions in 
human 
To compare the absorption 
physical mixture, lipid 
solution and solid dispersion 
Outcome of the study 
The dissolution and 
bioavailability were higher from 
the formulation with Gelucire 
44/ 14 than that from PEGs. 
Solid dispersion with lipid 
increased the bioavailability of 
the drug 5-fold compared to 
tablets because of improved 
dissolution rate 
Solid dispersion provided the 
highest AUC in dogs compared 
to physical mixture and lipid 
solution 
Reference 
Serajuddin, et al. 
1988 
Sheen et al. 1991 
Pozzi et al., 1991 
----.,__ 
Table 7. Lipid Systems: Solid Dispersions/Solutions (continued) 
Composition of lipid Drug used Purpose of the study Outcome of the study Reference 
formulation used 
Gelucires 43/01 , Theophylline To investigate the effect of Gelucires containing more PEG Sutananta et al. 
50102, 55/ 18, 50/ 13 MW= 180, humidity during storage of esters showed more changes than 1996 
Diuretic, Gelucires using dielectric, those containing more glycerides. 
vasodilator viscosity, thermal and No fundamental explanation was 
dissolution studies given for mechanism of dissolution 
differences under high humidity for 
both 
Unit dose contained DMP 323 To improve the Bioavailability was increased 50% Aungst et al. 
350 mg drug in HIV protease bioavailability of drug at using semi-solid Gelucire 44/14 1997 
Gelucire 44/14 inhibitor high doses formulation compared with the 
glycol vehicles 
0\ 
00 3.75% (w/v) drug in Nifedipine To develop a new method Two-phase dissolution system has Pillay and Fassihi, 
mixture of Gelucire MW = 346, for dissolution studies of been developed and used. It has 1999 
44/ 14 and Labrasol vasodilator lipid-filled capsules for been suggested to use in lipid based 
Nifedipine formulation as an alternative to 
USP method 
Solid dispersion of UC-781 To prepare and characterize Enhanced dissolution rate was Damian et al., 
drug was prepared at MW=335.5, solid dispersions of the drug obtained with solid dispersions 2000 
various concentration antiviral with PEG 6000 and compared with physical mixture 
with Gelucire 44/ 14 thiocarboxanili Gelucire 44/ 14 to improve and DSC, X-ray, IR were used in 
and PEG 6000 de dissolution properties characterization of the system 
/'.___ 
Table 8. Lipid Systems: Solid Lipid Nanoparticles 
Composition of lipid Drug used Purpose of the study Outcome of the study Reference 
formulation 
Mixtures of follows at - To investigate the gel Gel formed because of Westesen & 
different ratios formation of phospholipid- crystallization of melt-homogenized Siekmann, 1997 
Dynasan 116 stabilized SLN tripalmitate and it can be prevented 
Lecithin by the addition of co-emulsifier 
' Tetronic 908 
Pluronic F 127 
5% one of the lipid - To investigate the effect of Longer the fatty acid chains in the Olbrich & 
( cetylpalmiate, Dynasan 116 surfactant and chain length glycerides provided the slower the Muller, 1999 
or Dynasan 118) of fatty acid on enzymatic degradation. Cholic acid sodium 
0.5% one of the surfactant degradation of SLN accelerated the degradation while 
solution (Cholic acid poloxamer 407 slowed down 
0\ sodium salt, Lipoid E80, 
\0 Poloxamer 407 or Tween 80 
10% (m/m) Compritol 888 - To investigate long-term Crystallization occurred during the Freitas & Muller, 
ATO stability of SLN in terms of storage leading gelation 1999 
1.2% (m/m) Pluronic F68 crystallinity of lipid phase 
Water to make I 00% 
'\ 
Table 9.Lipid Systems: Cubic Phase 
Composition of Drug used Purpose of the study Outcome of the study Reference 
lipid formulation 
used 
- Glyceryl To form Cubic phase dipersion Lipohilic drugs incorporated Engstrom, 
monooleate called Cubosome™ and compare better to Cubosome than to 1990 
(GMO) with emulsion and liposome emulsion 
formulations 
- 10% (w/w) Griseofulvin To investigate the effect of cubic The solubility of drugs in mono- Chang and 
drug in 
MW=352, antifungal 
phase formed with GMO on glyceride and surface tension of Bodmeier, 
Glyceryl dissolution profiles of druP binding drugs affected the dissolution 1997 
monooleate Ibuprofen of drugs to mono-glyceride matrix profiles and phase transitions. 
(GMO) MW= 206, analgesic systems and the influence of the Above the certain concentrations, 
Propranolol addition of drugs on the phase the drugs having good solubility 
-.J MW= 259, ~-blocker behavior in glyceryl monooleate 
0 
transformed the cubic phase into 
an inverted hexagonal phase 
Cefazolin (50 and Cefazolin & To evaluate the ability of the cubic The enhanced stability of both Sadhale & 
200µg/g) and Cefuroxime phase gel to act as a chemical drugs in GMO cubic phase gel Shah, 1998 
cefuroxime stability enhancer has been demonstrated 
(200µg/g) in MW = 454 & 424, 
GMO antibiotics 
(. Table 10: Solubility of griseofulvin and nifedipine in lipid/Chremophor EL 
mixtures 
Lipid vehicle Lipid/Cremophor Griseofulvin solubility Nifedipine 
EL ratio (g/ g) (mg/g) (mean± SEM) solubility (mg/g) 
10/0 0.683 ± 0.008 3.359 ± 0.029 
Miglyol 810 9/1 0.867± 0.004 4.863 ± 0.043 
Glyceryl tri 8/2 1.001± 0.007 10.183 ± 0.087 
caprylate (Cs) 713 1.578± 0.008 17.940 ± 0.123 
6/4 2.249± 0.005 23.702 ± 0.091 
515 4.235± 0.025 18.276 ± 0.083 
CapmulMCM 10/0 4.031 ± 0.005 10.273 ± 0.091 
Glyceryl 9/1 6.542 ± 0.028 14.368 ± 0.037 
8/2 6.696 ± 0.059 16.738 ± 0.047 
mono- 7/3 6.069 ± 0.032 23.873 ± 0.089 
caprylate (Cs) 614 6.475 ± 0.048 23.720 ± 0.023 
515 5.915 ± 0.019 26.478 ± 0.124 
Capmul 10/0 3.292 ± 0.019 3.115 ± 0.111 
GMO 9/1 3.127 ± 0.008 8.878 ± 0.094 
Glyceryl 8/2 3.776 ± 0.043 11. 758 ± 0.087 
mono-oleate 713 5.235 ± 0.034 16.456 ± 0.108 
614 8.457 ± 0.062 18.591 ± 0.056 
(C1s:1) 
515 6.110 ± 0.059 24.825 ± 0.083 
Caprol 2GO 10/0 2.275 ± 0.006 3.026 ± 0.037 
2-glyceryl 9/1 2.916 ± 0.012 7.055 ± 0.148 
mono-oleate 8/2 3.551 ± 0.005 10.221 ± 0.097 
(C1s:1) 713 4.005 ± 0.025 14.657 ± 0.084 
614 4.278 ± 0.009 19.548 ± 0.174 
515 4.567 ± 0.025 24.143 ± 0.267 
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( TablelO: Solubility of griseofulvin and nifedipine in lipid/Chremophor EL 
mixtures (continued) 
Lipid vehicle Lipid/Cremophor Griseofulvin solubility Nifedipine 
EL ratio (gig) (mg/g) (mean± SEM) solubility (mg/g) 
10/0 1.386 ± 0.002 3.193 ± 0.099 
Caprol3GO 9/1 1.975 ± 0.015 6.217 ± 0.122 
8/2 
3-glyceryl 
2.494± 0.008 10.679 ± 0.165 
7/3 2.554± 0.005 12.353 ± 0.465 
mono-oleate 
6/4 3.133± 0.018 19.385 ± 0.345 
(C1s:1) 
515 3.900± 0.030 24.304 ± 0.655 
10/0 3.774 ± 0.018 16.983 ± 0.555 
Capmul PG-8 9/1 4.497± 0.028 19.256 ± 0.426 
8/2 4. 758± 0.020 23.304 ± 0.457 
Propylene 
7/3 5.342± 0.019 27 750 ± 0.589 
glycol mono- 614 7.883± 0.033 31.226 ± 0.891 
caprylate (Cs) 515 6.516± 0.186 40.032 ± 0.924 
10/0 2.197 ± 0.006 8.118 ± 0.243 
Capmul PG-12 9/1 2.376 ± 0.012 10.717 ± 0.094 
Propylene 8/2 3.410 ± 0.014 13.287 ± 0.243 
glycol mono- 7/3 4.250± 0.007 18.792 ± 0.145 
614 4. 755 ± 0.026 23.359 ± 0.456 
laurate (C12) 
515 6.067 ± 0.043 18.055 ± 0.754 
Capmul PG-18 10/0 1.913 ± 0.007 5.068 ± 0.035 
9/1 1.658 ± 0.012 8.728 ± 0.216 
Propylene 
8/2 2.255 ± 0.020 10.990 ± 0.556 
glycol mono-
7/3 2.280 ± 0.026 14.683 ± 0.423 
oleate (C1s:1) 614 2.929 ± 0.013 21.050 ± 0.589 
515 4.142 ± 0.044 30.176± 0.812 
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Figure 3. Effect of cooling rate on viscosity of wax based 
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( SECTION I 
OBJECTIVES 
a. To evaluate solvent properties the lipids available in the US using two poorly 
soluble drugs, nifedipine and griseofulvin. 
b. To select most suitable lipids and prepare nifedipine lipid formulation to 
evaluate its dissolution properties. 
c. To assess the bioavailability of the nifedipine formulations in beagle dogs and 
to seek a correlation of in vivo data to that of in vitro test results. 
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( 1. INTRODUCTION 
The use of lipid vehicles has generated considerable attention in recent years to 
improve the bioavailability of poorly soluble drugs. The well-known effect of food in 
improving the bioavailability of many poorly soluble drugs such as griseofulvin, 
carbamazepine and danazol is the evidence that lipids can be beneficial to drug 
absorption (Charman et al., 1992, 1993, 1997; Humberstone and Charman, 1997). 
Lipids can improve the bioavailability of drugs through several mechanisms. 
Enhancing the solubility/ dissolution of the drug is one of the commonly observed 
effects (Pozzi et al., 1991; Sheen et al., 1991; Charman et al., 1992; Shah et al., 1994; 
Matuszewska et al., 1996; Aungst et al., 1997). 
Although lipids have the potential for enhancing drug absorption, only few 
commercial formulations of lipid-based formulations are available on the market. 
These are cyclosporine (Sandimmune™ and Neoral™, Novartis), saquinavir 
(Fortovase™, Roche), ritonavir (Norvir™, Abbott) and fat-soluble vitamins. One of the 
reasons for rarity of commercially available lipid-based products is the physical 
complexity of lipids. 
Drug solubility in a lipid is the most important factor in the selection of a lipid as a 
vehicle. However, due to their physical complexity such as existing as mixtures, 
solubility of drugs in lipids is a poorly understood concept. Formulation scientists 
many times select an effective lipid that dissolves a given lipophilic drug by trial and 
error. The lipids that are screened for this purpose as routine are given in Table 1. In 
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( general, the lipids that contain a fatty acid distribution and ester combinations provide 
better solubility than purer ones. For example, Capmul MCM that contains caprylic 
(Cs) and capric acid (C10) provides better solubility than Capmul MCMC8 that 
contains only caprylic acid. Since liquid type lipid or lipid combinations are used in 
the oral formulations as routine, solubility studies are limited to oily vehicles. 
There are a number of studies to show the effects of the physiochemical properties of 
the drug on lipid solubility. The melting point and partition coefficient of the drugs are 
the key factors affecting solubility in trioleates (Yamaoka et aL 1983; Patton et al, 
1984; Mithani et al., 1995; Alvarez-Nunez and Yalkowsky, 2000 and Larsen et al., 
2002). However, systematic studies showing a relationship between lipid solubility of 
a drug and physicochemical properties of lipid are limited. Only Anderson and Marra., 
(1999) reported chemical properties that contributed solvent property of synthetic and 
natural oils, tributyrin and tricaprylin. It was shown that as the ester concentration of 
the lipid increased, the solubility of an investigational anti-HIV agent in the lipids 
used increased. It has been also shown that oils having larger molecular volumes 
(ethyl oleate, Miglyol 812 and soybean oil) solubilized testosterone less than the oils 
with smaller molecular volumes (ethyl butyrate and ethyl caprylate) (Malcolmson et 
al., 1998 and Warisnoicharoen et al., 2000). 
In general, solvent properties of lipids depend on the chemical, electrical and 
structural effects. The polarity, hydrophille-lipohille balance, ester concentration, 
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( solubility parameters, surface tension and molecular volume can play a role in their 
solvent property. 
Polarity of a solvent plays an important role in the solubility. Polar solvents are 
capable of solvating molecules through dipole interaction forces, particularly via 
hydrogen-bond formation, which is a major mechanism in the solubility of a 
compound. Polarity of solvents can be defined by dielectric constant (E), which is an 
important property related to the solubility and hydrophilic-lipophilic balance 
(Gorman and Hall, 1963 and 1964, Carstensen, J.T., 1971, Cave et al, 1979 and 
Rabaron et al. 1993). It has been shown that the solubility ofa solute decreased as the 
dielectric constant of solvent decreased (Carstensen et al., 1971, Trivedi et al., 1996). 
Therefore, dielectric constants of lipids can be evaluated to predict their solvent 
properties. 
An understanding of cohesive energy between the drug and the lipid molecules may 
help to determine how a lipid will behave as a solvent. Cohesion is result of the 
London forces, polar interactions and specific ones like hydrogen bonding (Hansen 
and Alan, 1971, Barton, 197 5). The most commonly used approach in quantifying the 
cohesion between a solvent and a solute is the solubility parameter,8, which is defined 
as the square root of the cohesive energy density, expressed as the energy of 
vaporization. 
8 =(CED) 112 = (LllivNm) 112 (1) 
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( Where CED is cohesive energy density ~Ev is the energy of vaporization and V m is 
the molar volume. 
This parameter may be useful to predict the solvating ability of a lipid or the lipid 
mixture. When solubility parameters of lipid and the drug are similar, they are 
expected to become miscible (Scatchard, 1931, Small, 1953, Krevelen and Hoftyzer, 
1972). Determining the solubility parameter of a lipid vehicle and thereby quantifying 
its cohesive energy may offer a solution for screening solvent properties of the lipid 
candidates. 
There are numbers of indirect and direct methods available that can be used to 
determine solubility parameter. The practical methods include vapor pressure or 
boiling point determinations, solubility/miscibility measurement in liquids with known 
cohesive energy, solution calorimetry, and surface energy measurements. 
Theoretically, and more often the group contribution method is used (Fedors, 1974, 
Samaha et al., 1990, Subrahmanyam et al., 1996, Hancock et al, 1997, Breitkreutz, 
1998, Ohta et al., 1999). According to this calculation, the solubility parameter: 
OF= [L:~e/L~v] 112 (2) 
Where ~e:The additive atomic group contributions for the energy of vaporization 
~v:The additive atomic group contributions for the molar volume 
In this study, the group contribution method given above (2) was used to calculate the 
solubility parameter from knowledge of the structural formula of the selected lipids 
and drug compounds. This approach is especially useful in the initial stages of the 
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( pharmaceutical research and development process, where the properties of a new 
chemical entity, which is very often in short supply, can be estimated in light of very 
little experimental data. Because of lipid's instability during heating, their boiling 
point often can not be obtained. Therefore, Fedor's method appears to be the most 
applicable one to calculate solubility parameters of lipids. 
The hydrophilic-lipophilic balance (HLB) was developed by Griffin to characterize 
the polarity of nonionic surfactants. Most of the lipids used in oral drug delivery have 
surface-active properties. For example, Capmul MCM has HLB value of 5-6 like 
Spans. Capmul MCM has surface tension of around 26 dynes/cm2. Like surfactants, 
the interaction between a lipophilic drug and the lipid can take place at the 
hydrophobic part of the lipid vehicle. HLB of surfactants like nonoxynols was 
correlated with their solubility parameters (Samaha and Naggar, 1988, Schott, 1984 
and 1995, Poulain et al., 1997). Similarly, such correlation may exist in lipids. If so 
this property can be a very useful tool to select a suitable lipid to dissolve a given 
drug. 
It has been also shown that surface free energy of solids was correlated well with 
solubility parameters (Samaha and Naggar, 1990). Therefore, surface tension, defined 
as the surface free energy change per unit area increase, can be also a useful tool to 
predict solvent property of lipids. 
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Saponification value is another important chemical property to predict the solvent 
power oflipids. It is defined as the weight of KOH used to saponify the ester and fatty 
acids. Therefore, it has been used to earlier obtain ester concentration and correlated 
well with solvent power of lipids (Anderson and Marra. 1999). 
Most of the commonly used solvents like water, ethanol and methanol are small 
molecules. Lipids differ from these solvents in terms of molecular weight and purity. 
Lipids like triglycerides are much larger molecules. Therefore, they cannot 
accommodate large amount of solute. It has been also shown that the oils with larger 
molar volume like ethyl oleate, Miglyol 812 and soybean oil solubilized testosterone 
less than the oils with smaller molar volumes (ethyl butyrate and ethyl caprylate) 
(Malcolmson et al., 1998). 
The aim of this study is to seek a relationship among the calculated and measured 
properties of lipids (MW, SAP, dielectric constant, HLB, solubility parameter and 
surface tension) on estimating the solubility of the selected poorly soluble drugs. The 
effect of hydrophilic head (glycerine vs. propylene glycol) and lipophilic tail (fatty 
acid chain length) of lipid has been also evaluated. Multiple linear regression (MLR) 
used to predict aqueous solubility of various drugs previously (Jorgensen and Duffy, 
2002) can be utilized to predict the solubility of lipophilic drugs in lipids. MLR is the 
technique of predicting a response by a linear combination of several variables. In this 
statistical analysis, the variables that are highly correlated toe ach other should not be 
used. Correlation coefficient between the properties given above and the solubility of 
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( the drugs in lipids and the contribution of each property can be found with MLR. The 
predictive ability of the model can be tested by regression coefficient which can be 
facilitated with a statistical package like JMP®. Nifedipine and griseofulvin have been 
selected as the model lipophilic drugs for this study. Nifedipine (Figure l) is a 
pyridine carboxylate and griseofulvin (Figure 2) is benzofuran dione. Both drugs have 
similar MW around 350. 
2. MATERIALS AND METHODS: 
2.1. Materials 
2.1.1. Model Drugs 
Nifedipine (Figure l) is a calcium antagonist, which is used to treat angina and 
hypertension. It is 3, 5-pyridinedicarboxylic acid, 1, - dihydro-2, 6-dimethyl-4-(2-
nitrophenyl)-, dimethyl ester. It has a molecular weight of 346.34. Nifedipine is 
practically insoluble in water (9.5 µg/ml at 25°C) and less soluble in ethanol. It is 
also light sensitive and converts to a nitrosophenylpyridine derivative when 
exposed to daylight and UV light. Therefore, all nifedipine experiments were 
carried out under yellow light. 
Griseofulvin (Figure 2) is an antifungal agent (7-Chloro-2', 4, 6-trimethoxy-6'-
methylspiro[benzofuran-2(3H), 1 '-[2]cyclohexene ]-3,4' -dione ). It is practically 
insoluble in water (18 µg/ml at 25°C) and slightly soluble in ethanol. It has 
molecular weight of 352.77. It is a classical example used as a model to study 
solubility related problems. 
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2.1.2. Lipids 
Table I. lists the lipids used in this study. Their fatty acids distribution is also 
presented in the same table. The lipids used were limited to the liquid. Selection of 
the liquid lipid has been made in such a way that the effect of hydrophilic head 
(glyceryl vs. propylene glycol), number of glyceryl groups and lipophilic tail (fatty 
acid chain lengths) can be investigated. There was no purification involved; they 
were used as obtained so that the findings can be helpful for the formulation 
scientists who use these materials as provided. 
2.2. Methods 
2.2.1. Experimental Solubility Determination 
The solubility of the drugs in each lipid vehicle and water was determined by 
adding an excess amount of the drug into 10 g vehicle and equilibrating the 
mixture at 25° ± 0.1°C for 72 hr. The mixture was centrifuged for 10 minutes and 
filtered through a 0.45µm filter. The amount of griseofulvin dissolved was 
determined by UV spectroscopy at a wavelength of328 nm. The calibration curve 
used for calculations is given in the appendix, Figure 1. Nifedipine dissolved was 
quantified by an HPLC method. A Hewlett Packard 1050 HPLC system with a UV 
detector (A =236 nm) was used. The stationary phase consisted of a micro 
Bondapak, C18 reverse phase column (3.9 x 300 mm, Waters Corp., Milford, MA). 
The mobile phase used was acetonitrile: methanol: water (2: 3: 3). The samples 
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( were diluted with methanol before the run. The flow rate was 1.0 mL/min with 30 
minutes of total run time per injection. 
A standard solution for Nifedipine (0.1 mg/mL) and lipid vehicles was prepared in 
methanol and was run with HPLC. The data acquisition was made using the 
software Turbochrome 6.1.1.0.0 (Perkin Elmer Corp, Wellesley, MA). Nifedipine 
standard curve for the method is given in the Appendix, Figure 2. HPLC 
chromatographs of lipids were also obtained to make sure that they don't interfere 
with nifedipine peak. All studies were performed in triplicate and coefficient of 
variance (CV) for precision of the experiments was± 2%. 
2.2.2. Surface Tension 
A Kruss K 12 Tensiometer (Kruss USA, Charlotte, NC) was used to determine 
surface tension. The plate method was selected. Lipids were equilibrated and 
surface tension was measured at 25°C with platinum plate cleaned with flame. 
2.2.3. Density Measurements 
The density of lipids was measured to use in molecular volume calculations. 
The density of a lipid was determined using a Paar Oscillating U-Tube (Anton 
PAAR, Ashland, VA) at 25°C. The instrument was calibrated with water. The U-
Tube was filled slowly with the lipid by making sure that there are no air bubbles. 
The display after equilibration was recorded as density (g/cm3). 
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2.2.4. FT-IR studies 
IR spectra for drugs, vehicle and solution were obtained using a Nicolet FT-IR 
with Attenuated Total Reflection (ATR) accessory (Nicolet Analytical, Madison, 
WI). The lipid and lipid solution of the drug was added to a sample holder. Solid 
samples were diluted in mineral oil. First, the spectra of lipids and the model drugs 
were taken (Appendix, Figures 3-15). The spectra of drugs solution in lipids were 
also recorded. Omnic software Version 6 (Nicolet Analytical, Madison, WI) was 
used to obtain spectra and for subtraction of lipid spectrum from solution 
spectrum. 
2.2.5. HLB calculation 
The HLB value of each lipid vehicle was estimated as follows: 
s 
HLB = 20 (1--) 
A 
(3) 
Where S is the saponification number of the ester and A is the acid number of the 
fatty acid. The HLB ofCapmul MCM (Glyceryl mono-caprylate), for which 
S=250 and A= 370, is 20 (1- 250/370) = 6.5. 
2.2.6. Calculation of Solubility Parameters 
Solubility parameters U>F ) of lipids and drugs were calculated using the group 
contribution method devised by Fedors (Eq. 2) 
Using equation (2), calculation of solubility parameter of oleic acid {CH3-(CH2) 6-
(Refer to Table II) 
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In this mode4 the contribution of hydrogen bonding is not included. Therefore, 
hydrogen bonding contribution was calculated as: 
DH= (5000m!V) Yi 
where mis the number of hydrogen donor and acceptors, and Vis the molar 
volume (MW/density) 
Total solubility parameter (&r) was calculated by adding hydrogen bonding 
contribution (8H) to the Fedor's solubility parameter (8F): 
OT = (OF 2 + DH 2 ) Yi 
(4) 
(5) 
Solubility parameters for griseofulvin and nifedipine were calculated by equation 
(5). Griseofulvin has 80 of14.77 (cal/cm3) 1n and nifedipine has~= 17.38 
(cal/cm3)w. These findings differ from the calculations that appear in the literature 
as 8a= 10.44 and~ =10.75 (Hancock et al, 1997, Squillante et al., 1997) due to 
addition of hydrogen bonding contributions. 
2.2.7. Refractive Index Measurements and Calculations of Dielectric 
Constant 
The refractive index (N) of each lipid vehicle was measured at 25°C using Abbe 
Mark II Model 10480 Digital refractometer (Sodium light at 589 wavelengths) 
(Cambridge Instrument Inc., Buffalo, NY). 
Dielectric constant (E) of each vehicle was calculated using the equation (6). 
N2 =c (6). 
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( 2.3. Statistical Analyses 
In order to evaluate the contribution of all the factors together, a stepwise linear 
regression analysis has been selected for multiple linear regression analyses of factors 
that affect the solubility of drugs. It is an approach to select a subset of effects for a 
regression model and facilitates searching and selecting among many models. 
Stepwise regression is used when there is little theory to guide the selection of terms 
for a model and the modeler. It can be done with forward or backward elimination 
methods. Forward brings in the regressor that most improves the fit, given that term is 
significant at the level specified by probability to enter. Backward removes the 
regressor that affects the fit the least, given that term is not significant at the level 
specified in probability to leave. Backward elimination method has been used in this 
study. The correlation coefficient (Rad/) and coefficient for each factor was 
determined. The model used for this analysis is as follows: 
(7) 
Where S is the solubility, ai is the coefficient determined by regression analysis to 
maximize R2, Ci is the factor (one of the physicochemical properties of lipid: MW, 
dielectric constant, saponification number, surface tension and solubility parameter), i 
is the set of factor and ao is the intercept of the linear regression. 
The effect of lipid's lipophilic tail (fatty acid chain length), hydrophilic head (glycerol 
or propylene glycol and number of glycerol) has been investigated using single factor 
ANOV A. The model used for this analysis: 
Sij=µ+fi+Eij (8) 
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( Where S is the solubility of the drug, i is the level of each factor: The factor lipophilic 
tail had 3, glyceryl vs. propylene glycol had 2 and number of glycerol had 3 levels, j is 
repetition (solubility experiments were conducted in triplicates),µ is mean, r is the 
effect of treatment and E is the random error. 
JMP Statistical Software version 4.0.4 (SAS Institute Inc, Cary, NC) has been used for 
all analyses. Significance level of 0.05 has been used for the analyses. The models 
adequacy has been checked with residual analysis and lack of fit. 
3. RESULTS AND DISCUSSION 
The saturated solutions of griseofulvin and nifedipine in each lipid when viewed under 
a microscope were all crystal free with exception of griseofulvin in glyceryl mono-
oleate (GMO) which probably dissolved slowly by forming liquid crystals, Figure 3. 
The FT-IR studies demonstrated no measurable chemical interaction between the 
drugs and lipid vehicles. Figure 4 is an example of the FT-IR spectrum for nifedipine 
in Capmul Pg-8. Possible interactions of a lipid and the drug may occur through the 
hydrogen bonding and the other polar and hydrophobic interactions. However, there is 
no changes in the band appearing at 3400 cm-1 corresponding to hydrogen bond 
stretching (0-H), at 1740 cm-1 corresponding to carboxylic acid and the bands 
between 1470 and 1200 cm-1 which correspond to C-H and 0-H bending. Since there 
is no chemical interaction was observed, the interaction between the lipid and the drug 
may be the result of London forces or polar interactions. 
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The experimental solubility results for griseofulvin in the tested lipids ranged from 
0.318 to 4.031 mg/g and the solubility of nifedipine from 0.322 to 16.983 mg/g (Table 
III). Glyceryl mono-caprylate (Capmul MCM) was the best solvent for griseofulvin 
increasing the solubility 224 times compared to water. For nifedipine, propylene 
glycol mono-caprylate (Capmul PG-8) was the best solvent and the solubility was 
increased 1790 times as compared to water solubility. 
Lipids used were better solvents for nifedipine than for griseofulvin in increasing 
solubility because nifedipine has higher lipophilicity with a log P of 4 (Squillante et 
al., 1997) compared to griseofulvin with log P of2 (Mithani et al, 1996 and Nelsen et 
al. 2001). The solubility values obtained were used to correlate them with solubility 
parameter, MW, polarity and surface tension oflipids that are given in Table IV. 
The solubility parameter calculated for griseofulvin is OG = 14.77 (cal/cm3) 112• Capmul 
MCM that has the closest solubility parameter to that of griseofulvin provided the 
highest solubility among all lipids used. However, the same correlation could not be 
observed with nifedipine. The calculated solubility parameter for nifedipine is o N = 
17.38 (cal/cm3)1!2 and the lipid that has closest solubility parameter is glyceryl mono-
caprylate/caprate (Capmul MCM; o = 15.12 (cal/cm3) 112) but the highest solubility is 
provided by propylene glycol mono-caprylate (Capmul PG-8). Overall, calculated 
solubility parameter appeared to be a poor predictor for the expected solvent effects of 
the lipids. 
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( The comparison of solubility of the drugs and HLB of lipids showed that only the 
solubility of griseofulvin correlated well with HLB of the lipids. As the HLB of the 
lipid increased, the solubility of griseofulvin increased, Figure 5, with a correlation 
coefficient of 0.9014. However, the solubility of nifedipine did not show any 
correlation with HLB of the lipids. 
Comparing the solubility of drugs against an individual property of the selected lipid 
did not show any common correlation. Therefore, stepwise analysis has been 
conducted to evaluate overall effects of all variables. The stepwise analysis has been 
selected because there are independent multiple variables. The factors included into 
analyses are MW, dielectric constant (DC), SAP, surface tension (Sn and solubility 
parameter (8). HLB was excluded from the the model because it is calculated using 
SAP value. Regression coefficient and significance (p) were evaluated to determine 
the weight of contribution of each property of lipids. 
Table V shows stepwise analyses steps for prediction of nifedipine solubility and 
Table VI for griseofulvin. As it can be seen from the tables, MW, DC, SAP and 
surface tension were significant factors for nifedipine (p<0.05). Solubility parameter is 
not significant factor (p>0.05) so that it has been removed from the model. On the 
other hand, SAP is not a significant factor for griseofulvin solubility while MW, DC, 
surface tension are significant factors (p<0.05). From these analyses, the relationship 
to estimate the solubility of nifedipine (Snif, mg/g) can be expressed as (Radj2 = 
0.8686): 
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( Snir= -173+ (-0.054)MW + (80.95)DC + (0.056)SAP + (0.52)ST (9) 
Where MW is molecular weight, DC is dielectric constant, SAP is saponification 
number and ST is surface tension (dyne.cm-2). 
The relationship to estimate the solubility of griseofulvin (Sgris, mg/g) can be 
expressed as: (Radj2 = 0.8187) 
Sgris = -24.61 + (-0.0082)MW + (14.14)DC + (-0.14)ST + (0.34)8 (10) 
Where MW is molecular weight, DC is dielectric constant, ST is surface tension 
(dyne.cm-2) and 8 is solubility parameter ((caVcm3) 112). 
The common propertie<> of the lipids that contribute for the solubilit'' of both drugs are 
r MW, dielectric constant and surface tension. The contribution of MW is the highest 
I 
for both drugs (R2 = 0.7721 for nifedipine and R2 =0.5701 for griseofulvin). However, 
the estimates of each property are different between two drugs indicating a major role 
of the drug in lipid solubility. Saponification value representative of ester 
concentration was not a commonly shared contributor for both drugs as opposed to 
previously shown (Anderson and Marra, 1999). Therefore, it cannot be generalized. It 
can be a contributor for more lipophilic drugs like nifedipine as opposed to 
griseofulvin. 
The effect of hydrophilic head (glycerine vs. propylene glycol, number of glyceryl 
groups) and lipophilic tail (fatty acid chain length) oflipid has been tested with 
ANOVA for both drugs in accordance with the model described in Section 2.3, 
96 
( Equation8. The results in Table VII showed that the effect of fatty acid chain length is 
significant for both drugs (p< 0.05). The solubility of drugs was increased as the alkyl 
chain decreased. Also, griseofulvin being more hydrophilic than nifedipine seems to 
be more sensitive to and affected from hydrophilic head changes. 
4. CONCLUSIONS 
In this study, it has been shown that the lipids used improved the solubility of 
nifedipine and griseofulvin compared to the solubility of drugs in water. Calculated 
solubility parameter was not sufficient to predict the solubility of drugs in the lipids. 
Calculated and measured properties of lipids analyzed with stepwise regression 
analyses showed that MW, dielectric constant, surface tension are the common factors 
( that govern the lipid solubility. However, the estimates of each factor were different 
for each drug indicating that the drug played important role in lipid solubility. Overall 
results showed that MW, dielectric constant, surface tension and fatty acid chain 
length contribute the solvent action of lipids. 
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Table I: Lipid vehicles used in this study 
Chemical Name Trade Names Fatty acid distribution* 
Oleic acid (C1s:1) Emersol6313 (Henkel) 75 % C1s:1 6% C1s:2 6% C16:2 5% C16 
3%Ct4:t 3%C14 2% C1s:3 
Glyceryl tri-oleate Captex GTO (Abitec) 92% C1s:1 4% C1s:2 3% C1s 
Caprylic (Cs) I Miglyol 810 (Sasol) 71% Cs 29% C10 
Capric (C 10) triglyceride Captex 300 (Abitec) 67%Cs 33% C10 
Mono-and di-glyceride of Capmul MCM (Abitec) 81% Cs 17.4% C10 
caprylic(C8)/capric(C 10) acid 
Glyceryl mono-oleate Capmul GMO (Abitec) 80% C1s:1 4%C16 4%C1s ll%C1s:2 
Diglycerylmonooleate Caprol 2GO (Abitec) 90%C1s:1 3%C1s 3%C1s:2 
Triglyceryl monooleate Capmul 3GO (Abitec) 90%C1s:1 3%C1s 3%C1s:2 
Propylene glycol monocaprylate Capmul PG-8 (Abitec) 99%Cs 1% Cto 
Porpylene glycol mono-laureate Capmul PG-12 (Abitec) 99% C12 
Porpylene glycol mono-oleate Capmul PG-18 (Abitec) 93%C1s:1 3%C1s 3%C1s:2 
Propyleneglycol dicaprylate Captex 200 (Abitec) 64%Cs 34%C10 2%C6 
(C8)/dicaprate (C 10) 
* C6: Caproic, C8: Caprylic, C10: Capric, C12: Laurie, C14: Myristic, Ct4:t: Myristoleic, C16: Palmitic, C 16:1: Palmitoleic, C 18: Stearic, 
C 18:1 : Oleic, C1 s:2: Linoleic and C1s:3: Linolenic acid 
( Table II: Group contributions to the energy of vaporization and the molar 
volume at 25°C for the functional groups of oleic acid 
Group Lie (cal/mo I) Liv(cm3/mol) 
1 CH3 1125 33.5 
14CH2 16520 225.4 
I COOH 6600 28.5 
2--CH= 2060 27 
Total 26305 314.4 
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( Table III: Experimental solubility results for nifedipine and griseofulvin 
Lipid vehicle Griseofulvin solubility Nifedipine solubility 
mg~ (mean± SEM, n=3) ma (mean± SEM, n=3) 
Emerso l 6313 (Henkel) 0.951 ± 0.006 0.3220 ± 0.0269 
Oleic Acid (Cts:1) 
Captex GTO (Abitec) 0.318 ± 0.015 1.3028 ± 0.0103 
Glyceryltrioleate(C1s:1) 
Miglyol 810 (Huls) 0.683 ± 0.008 3.3595 ± 0.0292 
Glyceryl tri caprylate(Cs) 
Capmul MCM (Abitec) 4.031 ± 0.005 10.2733 ± 0.0913 
Glyceryl monocaprylate(Cs) 
Capmul GMO (Abitec) 3.292 ± 0.019 3.1149± 0.1112 
Glycerylmonooleate (C1s:1) 
Caprol2GO (Abitec) 2.275 ± 0.018 3.0264 ± 0.03712 
Diglycerylmonooleate(C1s:1) 
Caprol 3GO (Abitec) 1.386± 0.002 3.1930 ± 0.0996 
3 glycerylmonooleate (C1s:1) 
Capmul PG-8 3.774 ± 0.018 16.9831 ± 0.5556 
Propy leneglyco l 
monocaprylate (Cs) 
Capmul PG-12 2.197 ± 0.006 8.1186 ± 0.2429 
Propyleneglycol 
monolaurate (C12) 
Capmul PG-18 1.913 ± 0.007 5.0682 ± 0.0353 
Propyleneglycol 
monooleate (C1s:1) 
Captex 200(Abitec) 0.817 ± 0.004 4.1052 ± 0.0668 
propylene glycol 
dicapry late( Cs) 
water 0.018 ± 0.001 0.0095± 0.0005 
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Table IV: Calculated and measured properties of lipids used 
Lipid SAP () HLB Density MW Molar Refractive Dielectric 
( cal/cm3) 112 (g/cm3) volume ( cm3) index constant 
Oleic acid - 10.54 1 0.8886 282 307 1.4585 2.1272 
Captex GTO 190 10.63 1 0.9123 863 946 1.4685 2.1565 
Miglyol810 340 12.16 l.5 0.9437 495 525 l.4477 2.0958 
CapmulMCM 250 15.12 6.5 1.0022 275 273 1.4508 2.1048 
CapmulGMO 165 12.12 4 0.9451 490 518 1.4688 2.1574 
Caprol2GO 141 12.26 5 0.9814 421 429 1.473 2.1697 
Caprol3GO 143 14.29 6 0.9776 494 505 1.4728 2.1691 
CapmulPG-8 300 13.19 5 0.9387 202 215 1.4363 2.0630 
CapmulPG-12 225 12.26 4 0.9183 258 245 1.4444 2.0863 
CapmulPG-18 162 11.44 3.5 0.9096 340 374 1.4592 2.1293 
Captex 200 329 11.82 3 0.9173 328 375 1.4397 2.0727 
SAP: Saponification, HLB: Hydrophille-lipophille balance, MW: Molecular weight, 8: Solubility parameter 
-, 
Surface tension 
(mN/m) at 25°C 
32.40 
32.78 
29.58 
28.2 l 
31.36 
29.77 
37.61 
29.3 
29.53 
32.15 
30.17 
( Table V. Linear regression analysis with stepwise fit for solubility of nifedipine 
Stepwise Regression Control 
Alpha 0.05 
Current Estimates 
SSE DFE MSE RSquare RSquare Adj Cp AIC 
58.907758 19 3.100408 0.8914 0.8686 4.020048 31.55006 
Parameter Estimate nDF SS "F Ratio" "Prob>F" 
Intercept -173.23706 1 0 0.000 1.0000 
MW -0.0545075 1 117.7817 37.989 0.0000 
Dielectric 80.958237 1 14.02595 4.524 0.0467 
constant 
SAP 0.05630996 1 38.5523 12.435 0.0023 
Surface tension 0.5228523 1 23.83656 7.688 0.0121 
Solubility 1 0.065537 0.020 0.8890 
parameter 
Step History 
Step Parameter Action "Sig Seq SS RSquare Cp 
Prob" 
1 MW Entered 0.0000 418.9455 0.7721 17.824 
2 Dielectric constant Entered 0.0443 22.12014 0.8129 13.057 
3 SAP Entered 0.0457 18.78224 0.8475 9.3117 
4 Surface tension Entered 0.0121 23.83656 0.8914 4.02 
5 Solubility parameter Entered 0.8890 0.065537 0.8916 6 
6 Solubility parameter Removed 0.8890 0.065537 0.8914 4.02 
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( Table VI. Linear regression analysis with stepwise fit for solubility of griseofulvin 
Stepwise Regression Control 
Alpha 0.05 
Current Estimates 
SSE DFE MSE RSquare RSquare Adj Cp AIC 
3.9353886 19 0.207126 0.8502 0.8187 4.2928 -33.3931 
Parameter Estimate nDF SS "F Ratio" "Prob>F" 
Intercept -24.609009 1 0 0.000 1.0000 
MW -0.0082946 1 7.90434 38.162 0.0000 
Dielectric constant 14.1378874 1 2.821204 13.621 0.0016 
SAP 0.062991 0.293 0.5951 
Surface tension -0.1443072 1 2.321461 11.208 0.0034 
Solubility parameter 0.34747891 1 3.551889 17.148 0.0006 
( 
Step History 
Step Parameter Action "Sig Prob" Seq SS RSquare Cp 
1 MW Entered 0.0000 14.97806 0.5701 32.51 
2 Solubility parameter Entered 0.0065 3.423615 0.7004 18.596 
3 Dielectric constant Entered 0.0342 1.61624 0.7619 13.084 
4 Surface tension Entered 0.0034 2.321461 0.8502 4.2928 
5 SAP Removed 0.5951 0.062991 0.8502 4.2928 
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Table VII. Effect of hydrophilic head (glyceryl/propylene glycol and# of glyceryl group) and lipophilic tail (fatty acid chain 
length) on solubility of nifedipine and griseofulvin analyzed by single factor ANOV A 
Functional group Lipids Nifedipine Griseofulvin 
i=Level Solubility(mg/g) F ratio p Solubility(mg/g) F ratio p 
Factor 1: CapmulMCM 10.273 4.031 
I 
Glyceryl vs. CapmulGMO 3.115 3.292 
1.1993 0.1918 0.3994 0.0950 
propylene glycol CapmulPG8 16.983 3.774 
2 
CapmulPG18 5.068 1.913 
I CapmulGMO 3.115 3.292 
Factor 2: 
2 Caprol2GO 3.026 0.2258 0.8044 2.275 2207.144 0.0001 
# of glyceryl group 
3 Caprol3GO 3.193 1.386 
Factor 3: 1 CapmulPG8 16.983 3.774 
220.30 
Fatty acid chain 2 Capmu!PG12 8.118 0.0001 2.197 3951.706 0.0001 
08 
length 3 CapmulPG18 5.068 1.913 
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Figure 1. Nifedipine chemical structure 
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Figure 2. Chemical structure of griseofulvin 
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Figure 3: Liquid crystal formed with griseofulvin in glyceryl mono-oleate. 
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( 1. INTRODUCTION 
The use of lipid vehicles has generated considerable attention in recent years for 
improving the bioavailability of poorly soluble drugs as one of the approaches to 
improve their oral bioavailability. One of the advantages of lipids in delivery of poorly 
soluble drugs is to improve the bioavailability of drugs by enhancing 
solubility/dissolution (Pozzi et al., 1991; Sheen et al., 1991; Charman et al., 1992; 
Shah et al., 1994; Matuszewska et al., 1996; August et al., 1997). 
Lipid-based drug development phases can be classified as (I) selection of lipid 
vehicle/sand design of dosage form, (II) dissolution, product performance and 
bioavailability testing. Selection of the best lipid vehicle is one of the important chores 
in lipid formulations. 
A suitable solvent for the lipid formulation usually contains a lipid and a surfactant. 
Depending on the solubility/concentration of the dug incorporated, saturation can 
influence the absorption of the drug. A lipid that is suitable for a drug delivery system 
must be safe and, therefore, the first requirement for these excipients is to be classified 
as GRAS (generally recognized as safe) materials. The potential toxicity of the 
surfactant incorporated should be considered carefully especially in chronic use. This 
evaluation includes not only the type of the surfactant but also its concentration/dose 
(Swenson et al., 1994). 
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( To optimize the lipid solubility and particularly the release of the drug, addition of a 
co-solvent and surfactant/scan be useful. Ratios of the co-solvent, lipid and surfactant 
should be optimized to avoid potential precipitation of the drug in the gastro-intestinal 
(GI) media. To understand the performance of the formulation in GI media, the lipid, 
surfactant, co-solvent and drug combinations can be evaluated upon aqueous dilution 
using the phase diagrams (Shah et al., 1994; Constantinides, 1995 and Kim et al., 
2000). Since only few lipids are capable of maintaining the drug in the solution form 
in the GI fluid, the surfactant addition may be necessary to maintain a good 
dispersibility of the drug. 
Based on these facts, the solubility of a drug in a lipid is an important factor in 
selection of the lipid as a vehicle. This issue has been discussed earlier by the same 
group (Manuscript 2). Although, MW, fatty acid chain length and dielectric constant 
were determined as the common contributors to the solvent property of a given lipid, 
specific drug - lipid interactions are still important factors. 
On the other hand, release of a drug from the vehicle was found to be an inverse 
function of its solubility in the lipid system (Armstrong and James, 1980). Therefore, 
chemical potential (concentration/solubility) and partitioning of the drug from the lipid 
to the immediate aqueous environment should be considered in lipid-based 
formulation design. 
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( HLB plays an important role in the selection of the lipid vehicles in such formulations. 
Even though most of the lipids have no surface-active properties, medium chain 
mono-glycerides exhibit surfactant properties. HLB provides reliable practical 
information about the water miscibility of the lipid and the surfactant. HLB of 
polysorbates varied the dissolution ofaratinoid (Bachynsky et al., 1994). Shah et al. 
(1994) showed that HLB of the oil surfactant mixtures affected the release property of 
a freely oil soluble drug. 
Dissolution testing for poorly soluble drugs requires modification of the routinely used 
media. Incorporation of a surfactant into the dissolution media improved dissolution of 
poorly soluble drugs such as REV5901, UC781 (Serajuddin, 1988; Roman, 1999; 
Dressman and Reppas, 2000 and Damian et al., 2000). The mechanism of surfactant 
facilitated dissolution of poorly soluble drugs has been reviewed by Crison et al. 
( 1996) and summarized as mice Ile-facilitated dissolution. Polysorbate 80, sodium 
lauryl sulfate and polyoxyl-35 castor oil are the most commonly used surfactants 
added to the medium to improve dissolution of the poorly soluble drugs. 
The surfactant concentration selected depends on the critical micellar concentration of 
the surfactant and micellar solubility of the drug. The type of surfactant used in the 
dissolution medium is also important because of the possible interactions with the 
capsule shells as it happens with sodium lauryl sulfate (SLS). This anionic surfactant 
may interact with cationic charges of gelatin at gastric pH (Pillay and Fassihi, 1999). 
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( These interactions may retard the disintegration of the capsule shell and thus 
dissolution of the drug. 
Larsen et al., (2002 and 2000) demonstrated that partitioning of testosterone from the 
vegetable oils into a pH 6 buffer was correlated with in vitro release rates. Viscosities 
of oils have not influenced the release of the drug. However, the viscosities studied 
were very close to each other. 
In the lipid based formulations, the effect of the properties oflipids on dissolution rate 
and extent of the drugs has been hardly studied. Therefore, in this study, formulations 
of nifedipine, developed with different classes of lipids and a surfactant combination, 
were examined to investigate the effect of surfactant on the solubility and dissolution 
of the drug. The effects ofphysicochemical properties of lipids on dissolution of 
nifedipine were evaluated. Effect of particle size and partitioning behavior of 
nifedipine on dissolution properties was also examined. 
2. MATERIALS AND METHODS 
2.1. Materials 
Lipids that are used for this study listed in Table I were selected based on their class 
and GRAS (Generally Recognized as Safe) status. The selected lipids included 
glycerides (glyceryl tri- caprylate/caprate, glyceryl mono-caprylate/caprate and 
glyceryl mono-oleate), polyglycerol (diglyceryl mono-oleate and triglyceryl mono-
oleate) and propylene glycol esters (propylene glycol mono-caprylate, -laurate and -
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oleate). By selecting these lipids, the effects of hydrophilic (glyceryl, polyglycerol and 
propylene glycol) and hydrophobic (fatty acid chain) groups oflipids on the 
dissolution can be determined. The fatty acid distributions of lipids are also given in 
the same table. The measured/calculated properties of the lipids (HLB, density, MW, 
polarity and viscosity) were summarized in Table IL The details of these 
measurements/calculations are already given in the Manuscript II. Because there is no 
purification involved in the formulations with lipids, they were used as obtained. 
The model drug chosen for this study was nifedipine, a calcium antagonist that is used 
to treat angina and hypertension. It is 3, 5-pyridinedicarboxylic acid, 1, - dihydro-2, 6-
dimethyl-4-(2-nitrophenyl)-, dimethyl ester. It has a molecular weight of 346.34. 
Nifedipine is practically insoluble in water (9.5 µg/mL at 25°C) and less soluble in 
ethanol. It is also light sensitive and converts to a nitrosophenylpyridine derivative 
when it is exposed to daylight and UV light. Therefore, all nifedipine related 
experiments were carried out under yellow light. 
Cremophor EL (BASF Corp., Mount Olive, NJ), polyoxyl 35 castor oil, was used as 
the surfactant to improve the water miscibility of lipids. Cremophor EL 
(Polyoxyethyleneglycerol triricinoleate 35) is a liquid non-ionic surfactant with a 
critical micelle concentration (CMC) of0.0015 % w/v (Figurel). It is produced by the 
chemical reaction of ethylene oxide with castor oil. The major components of 
Cremophor EL are tri-glycerides which contain about 87% ofricinoleic acid. The 
surfactant is presently used as a vehicle in the pharmaceutical preparations to increase 
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( the solubility of lipophilic drugs, including cyclosporine A and paclitaxel (Sparreboom 
et al., 1996 and Meyer et al., 2001). 
2.2. Methods 
2.2.1. Solubility Determination 
The mixtures of Cremophor EL and lipid vehicles shown in Table I were prepared at 
varying lipid/surfactant ratios of 10/0, 9/1, 8/2, 7/3, 6/4, 515 w/w, which corresponds 
to 0, 10, 20, 30, 40 and 50% (w/w) Cremophor EL concentration, respectively. Visual 
observation of these mixtures was recorded. All lipid-surfactant combinations 
produced clear solutions except Miglyol 810, which formed cloudy mixtures at all 
ratios. 
The solubility of nifedipine was determined in each lipid-surfactant combination and 
in Simulated Gastric Fluid (SGF) by adding an excess amount of the drug into 10 g of 
solvent and equilibrating the mixture for 72 hr. at 25° ± 0.1°C for lipid/surfactant 
mixtures and 37° ± 0.1°C for SGF. The mixture was centrifuged for 10 minutes and 
filtered through a 0.45µm filter. The amount of nifedipine dissolved was determined 
by an HPLC method. 
A Hewlett Packard 1050 HPLC system with a UV detector (A. =236 nm) was used for 
nifedipine determination. The stationary phase consisted of a micro Bondapak, C 18 
reverse phase column (3.9 x 300 mm, Waters Corp., Milford, MA). The mobile phase 
used was acetonitrile: methanol: water (2: 3: 3) combinations. The samples were 
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diluted with methanol before the runs. The flow rate used was I .0 mL/min with 30 
minutes of total run time per injection. The data acquisition was made using the 
software Turbochrome 6.1.1.0.0 (Perkin Elmer Corp, Wellesley, MA). All studies 
were performed in triplicate. 
2.2.2. Interfacial Tension 
A Kruss K 12 Tensiometer (Kruss USA, Charlotte, NC) was used to determine the 
interfacial tension between the selected lipid and simulated gastric fluid (SGF), USP. 
The ring method was selected for the measurements. Both the lipids and SGF were 
used at 37°C. 
All the lipids used except Capmul MCM in Table I were less dense than SGF, USP. 
First, surface tension of the lipids was measured in a vessel then the vessel was 
emptied and cleaned. The heavy phase (SGF) was placed in the vessel, and then the 
ring was dipped in the liquid. The lipids were slowly added into the vessel by making 
sure no mixing occurred at the interface. Interfacial tension was determined by pulling 
the ring away from interface, the "pull" method. 
2.2.3 Formulation Development 
Among all surfactant/lipid mixtures, the ones containing 0, 10, and 40% w/w 
Cremophor EL have been selected for formulation development of nifedipine. The 
drug (10 mg) was added to the lipid/surfactant combination ( 4.5 g) and mixed in a 
shaker at the room temperature until it was completely dissolved. The final solutions 
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that were examined under a polarizing microscope were crystal-free. The solutions 
obtained were filled into "000" size hard-gelatin capsules and sealed with a bending 
solution that contained 20% w/v gelatin, 0.8% w/v polysorbate80 and water to make 
final volume 100 mL. The capsules were kept at the room temperature and assayed for 
nifedipine. The assay conducted using the HPLC method showed that the formulations 
were stable at the room temperature for two months containing 100 ± 2% nifedipine. 
2.2.4. Dissolution Test 
The USP II apparatus with paddle at a speed of 50 rpm and a temperature of37°± 
0.1°C was used to obtain dissolution profiles for the nifedipine lipid capsules. 
Simulated gastric fluid (pH =1.2, 900 mL) was used as the dissolution medium. Since 
the solubility of nifedipine is low, Cremophor EL was added to dissolution medium to 
increase the solubility of drug. Cremophor EL concentration of 3% (w/v) was selected 
to increase the solubility of nifedipine (Table III) and can differentiate dissolution of 
nifedipine from different formulations. 
Four capsules that have total of 10-mg drug were placed in capsule cages and dipped 
into the dissolution medium Samples (3 mL) were withdrawn using a syringe that was 
attached to a cannula with a 10 µfilter at 3, 5, 8, 10, 15, 20, 40 and 60 minutes. The 
withdrawn sample was replaced with 3 mL fresh dissolution medium. The amount of 
dissolved nifedipine was determined by the HPLC method as explained in Section 
2.2.1. 
( 
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( The percentage of nifedipine dissolved at 60 minutes was taken as the dissolution 
extent of the formulation. The dissolution rates were calculated using the Kitalllwa 
equation (Pillay and Fassihi, 1999): 
Ct = Co. ekt or 
ln ( C1) = Co - kt Equation 1 
where Ct is the remaining concentration of nifedipine at time t, Co is the initial 
concentration and k is the dissolution rate. Therefore, the slope of the plot ln (C1) vs. 
time in the linear region was taken as the dissolution rate. 
2.2.5. Partition Coefficient 
Partitioning of nifedipine from a respective formulation to the dissolution medium was 
obtained by mixing an equal amount of formulation and SGF + 3% Cremophor EL for 
1 hr at 25°C. The aqueous and oily phases of the mixture were separated by 
centrifuging the mixtures for 10 min at 2000 rpm. The oily phase separated was 
assayed for nifedipine. 
2.2.6. Particle Size Measurement 
Light scattering was used for the particle size measurements of the formulations that 
were obtained by dissolving them in SGF. The dissolution conditions were used for 
the particle size determination. Four capsules that have total of 10-mg drug were 
placed in capsule cages and dipped into the dissolution medium (900 mL), containing 
3% w/v Cremophor EL. 5 mL sample was withdrawn at I 0, 20, 40 and 60 minutes and 
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the particle sizes were measured using a Dynamic Light Scattering (Brookhaven 
Instrument Corp. Holtsville, NY). The measurement duration was one minute at the 
wavelength 488 nm and the detector angle 90°. Polydispersity index monitored was 
within 0.2% range. 
2.2. 7. Statistical Analyses 
The effect of Cremophor EL concentration on the solubility of nifedipine in lipids has 
been analyzed using linear regression. The model used is expressed as: 
Equation 2 
Where SN is the solubility of nifedipine (mg/g) in the mixture, SL is the intercept and 
represents the solubility of nifedipine (mg/g) in the lipid, Cs is the surfactant 
concentration(% w/w) and a is the slope and represents solubility rate. Correlation 
coefficient (Rad/) has been obtained. Goodness of fit test has been performed using 
Shapiro-Wilk hypothesis. For the Shapiro-Wilk test, a test statistic, W, is calculated 
and is used to test following hypotheses: 
Ho: The distribution is normal distribution 
Ha: The distribution is different from normal distribution 
If the probability of Wis higher than 0.05, the conclusion is fail to reject H0. 
Similarly, the effect of physicochemical properties of lipids, partitioning of nifedipine 
and particle size of nifedipine lipid-based formulations on dissolution has been 
analyzed using a simple linear regression analysis and correlation coefficient (Rad/) 
has been obtained. Goodness of fit test has been performed. 
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JMP Statistical Software version 4.0.4 (SAS Institute Inc, Cary, NC) has been used for 
all analyses. 
3. RES UL TS AND DISCUSSIONS 
3.1. The Role of Cremophor EL and on the Solubility and Dissolution of 
Nifedipine in Lipids 
The mixtures of lipid and Cremophor EL were clear except the 
Migl yo 181 O/Cremophor EL mixtures. The solubility of nifedipine in these mixtures is 
given in Table IV. As it can be seen from the results, addition 10-50% (w/w) of 
Cremophor EL increases the solubility of the drug around 10 to 600 times. Surfactant 
related increase in solubility(%) resuhs in Table IV showed that the highest percent 
increase was observed with Caprol 2GO (662%), which has the lowest nifedipine 
solubility and the lowest percent increase was observed with Capmul Pg-8 (12%), 
which provided the highest solubility for nifedipine. These results indicated that the 
effect of surfactant on the solubility ofnifedipine is more dominant, if the solubility of 
the drug in a lipid is low. The increase in solubility is proportional to the amount 
surfactant added, Figure 2 and the surfactant concentration and solubility obeyed: 
Equation 3 
All the statistical parameters, the slope (a), intercept SL (solubility of nifedipine in 
lipid) and correlation coefficient (Rad/) values obtained using Equation2 are tabulated 
in Table V. Goodness of fit test showed that normal distribution is followed for all 
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( lipids (p >0.05) and the model is adequate. Data in Table V also showed that slopes 
are the same for the same homolog series of lipids . For example, polyglycerols like 
Capmu!GMO (Glyceryl mono-oleate), Caprol2GO (Di-glyceryl mono-oleate) and 
Caprol3GO (Tri-glyceryl mono-oleate) have a slope of 0.41 and propylene glycol 
esters namely CapmulPG-8 (Propylene glycol mono-caprylate), CapmulPG-12 
(Propylene glycol mono-laurate) and CapmulPG-18 (Propylene glycol mono-oleate) 
have the slope around 0.38. The increasing surfactant concentration affected 
polyglycerol esters more than propylene glycol esters because the effect of surfactant 
on the solubility of nifedipine is more dominant with lipids dissolves the drug at lower 
extent. 
Dissolution profiles of the formulations that contained Cremophor EL showed that 
addition of 10% (w/w) surfactant in the formulation increased the rate of dissolution, 
Figure 3. An additional increase of surfactant in the formulation did not show further 
difference, regardless of the type of lipid. Figure 3 is an example to the dissolution 
performance of 10 -40% Cremophor EL containing nifedipine lipid formulation. 
Overall findings indicated that the presence of 10% Cremophor EL has hidden the 
variations involved in the dissolution caused by the lipids because micelle-facilitated 
dissolution takes over when there is sufficient surfactant presents in the formulation. 
3.2. Effect of Lipids on Nifedipine Dissolution 
The dissolution profiles of the formulations containing 10 mg nifedipine, 4.5 g of lipid 
and no surfactant are given in Figure 4. The highest and complete dissolution of 
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( nifedipine was obtained with Capmul MCM. Although the highest solubility of 
nifedipine was obtained in Capmul PG-8, it showed the lowest dissolution rate and 
extent for nifedipine. 
When the dissolution performance of the drug in a lipid series containing increasing 
fatty acid chain length compared, it was found that increasing chain length increased 
the dissolution rate and extent, Figure 5. The decrease in solubility of nifedipine with 
increasing fatty acid chain length may be the reason of the increment observed in the 
dissolution rate and extent. However, Table IV and Figure 4 demonstrated that 
solubility of nifedipine in Capmul MCM (glyceryl mono-caprylate/caprate) is similar 
to Capmul PG-8 solubility (Propylene glycol mono-caprylate) and yet Capmul MCM 
I 
provided much higher dissolution extent and rate. This occurrence suggests the role of 
' 
additional factors that may influence the dissolution of the drug from the lipids. These 
factors may be partitioning behavior of the drug, viscosity, polarity and density of the 
lipid. 
The dissolution rate and the extent of nifedipine given in Table VI compared with the 
solubility of the drug in the lipids, physicochemical properties of lipids (HLB, density, 
viscosity and interfacial tension) given in Table II showed that the effect of each factor 
is significant on dissolution rate and extent (p<0.005 with one way ANOV A). When 
the drug has high lipid solubility, lipid tends to keep the drug itself and does not Jet it 
release into aqueous medium. However, if the lipid is hydrophilic which can be 
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defined by HLB, interfacial tension, polarity, dissolution extent of the drug can be 
improved highly like it happens in Capmul MCM (96% dissolved in an hour). 
Density and viscosity were the other important properties of lipids affected dissolution 
rate and the extent of nifedipine, Tables II and VI. Relatively low density of the lipid 
resulted in floating of the formulation on surface of the dissolution fluid and slowed 
the release of the drug. Also as the viscosity of the lipid increased, the mixing time of 
the formulation was extended hence the dissolution rate and the extent was lowered. 
The dissolution performance of nifedipine in the lipids was further evaluated using 
two parameters; dissolntion extent and rate of nifedipine from each lipid given in 
Table VI. These values used to investigate the contribution of each factor to 
dissolution parameters. The statistical evaluations were carried out with the linear 
regression analyses. Among individual tests, only meaningful relationship was found 
between dissolution extent and partition coefficient of the drug (Radj2 = 0.991). 
Partition coefficient of nifedipine from formulations to the dissolution medium has 
been given in Figure 6. The drug partitioned in propylene glycol (PG) esters in the 
highest order. The increasing fatty acid chain from C8 to C18 decreased the partition 
coefficient from 9.6 to 7.8. Partitioning of drug from lipid to aqueous phase decreased 
as the solubility of drug increased in the lipid. Dissolution extent was significantly 
affected by partitioning, Figure 7. As the partition coefficient of drug from increased, 
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dissolution rate decreased producing a correlation coefficient of Rad/= 0.991 
between dissolution extent and partition coefficient of nifedipine. 
Particle size of the lipid-formulation in the GI fluid can also be an important factor 
that affects the dissolution of nifedipine. The smallest particle size was obtained from 
Capmul MCM which provided as small particle as the Miglyol810/CremophorEL 
mixture did, Table VII. During one hour mixing, the particle size of formulation did 
not change by time. The linear regression analyses showed that the particle size of 
each lipid at 60 minutes was correlated well with the dissolution extent at 60 minutes 
(R2adj =0.9758 and p=0.1733 for goodness of fit) and partition coefficient of 
nifedipine (R2adj =0.9835 and p= 0.3146 for goodness of fit). As the particle size 
increased, dissolution extent decreased and partition coefficient (Po/w) increased, 
Figure 8. These results also confirm the findings by Shah et al., (1994). As the particle 
size decreases, the surface area increases so that dissolution enhances. 
4. CONCLUSION 
Incorporation of Cremophor EL, a nonionic surfactant, into lipid-based nifedipine 
formulation enhanced the solubility and dissolution of nifedipine. The solubility of 
nifedipine showed a linear correlation with surfactant concentration. While solubility 
rate was dependent on the type of lipid used, the dissolution of nifedipine in presence 
of surfactant was the same regardless of lipid used. 
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( Dissolution of nifedipine from lipids showed that as the fatty acid chain length 
increases, the dissolution rate increases due to lower solubility of nifedipine in the 
lipids that have higher chain length. The effect of lipids on dissolution rate and extent 
of nifedipine investigated showed that even though physicochernical properties of 
lipids (HLB, interfacial tension, viscosity, density) and solubility of nifedipine in 
lipids play role, only partitioning of the drug from lipid to aqueous medium and 
particle size of the formulation in dissolution medium were provided a good 
correlation with dissolution extent of nifedipine. 
5. ACKNOWLEDGMENTS 
This study is part of Ms. Dumanli's Ph.D. dissertation research supported by 
Hoffmann-La Roche. The research was conducted at Hoffmann-La Roche facilities in 
Nutley, NJ. 
6. REFERENCES 
l. Armstrong, N.A., James, K.C., 1980. Drug release from lipid based dosage forms. 
II. Int. J. Pharm., 6, 195-204. 
2. Aungst, B.J. , Nguyen, N.H., Rogers, N.J., Rowe, S.M., Hussain, M.A., White, S.J., 
Shum, L., 1997. Amphiphilic vehicles improve the oral bioavailability of a poorly 
soluble HIV protease inhibitor at high doses. Int. J. Pharm., 156, 79-88. 
3. Bachynsky, M.O., Shah, N.H., Patel, C.I., Malick, A.W., Factors affecting the 
efficiency of a self-emulsifying oral drug delivery, Drug Dev. Ind. Pharm., 23(8): 
809-816 ( 1997) 
132 
( 
( 
4. Channan, S.A., Charman, W. N., Rogge, M.C., Wilson, T.R., Dutko, F.J., Pouton, 
C.W., 1992. Self-emulsifying drug delivery systems: formulation and 
biopharmaceutic evaluation of an investigational lipophilic compound. Pharm. 
Res., 9(1), 87-93. 
5. Constantinides, P.P., 1995. Lipid microemulsions for improving drug dissolution 
and oral absorption: Physical and biopharmaceutical aspects. Phann. Res., 12 (11), 
1561-1572. 
6. Crison, J.R., Shah, V.P., Skelly, J.P., Amidon, G.L., 1996. Drug dissolution into 
micellar solutions: Development of a convective diffusion model and comparison 
to the film equilibrium model with application to surfactant-facilitated dissolution 
of carbamazepine, J. Phann. Sci., 85 (9): 1005-1011 
7. Damian, F., Blaton, N., Naesen, L., Balzarini, J., Kinget, R., Augustijns, P., 
Mooter, G.V., 2000. Physicochemkal characterization of solid dispersions of the 
antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14, Eur. J. 
Phann. Sci., 10: 311-322 
8. Dressman, J.B., Reppas, C., 2000. In vitro-in vivo correlations for lipophilic, 
poorly water-soluble drugs. Eur. J. Phann. Sci., ll(Suppl.2), S73-S80. 
9. Fredholt, K., Larsen, D.H., Larsen, C., 2000. Modification of in vitro drug release 
rate from oily parenteral depots using a formulation approach, Eur. J. Pharm. Sci., 
11: 231-237 
10. Kim, H.J., Yoon, K.A., Hahn, M., Park, E.S., Chi, S.C., 2000. Preparation and in 
vitro evaluation of self-microemulsifying drug delivery systems containing 
idebenone, Drug Dev. Ind. Pharm., 26 (5): 523-529 
133 
r 
( 
11. Larsen, D. H., Fredholt, K., Larsen, C., Assessment of rate of drug release from oil 
vehicle using a rotating dialysis cell, Eur. J. of Ph arm. Sci., 11: 223-229 (2000) 
12. Larsen, D.B., Parshad, H., Fredholt, K., Larsen, C., Characteristic of drug 
substances in oily solutions. Drug release rate, partitioning and solubility, Int. J. 
Pharm., 232: 107-117 (2002) 
13. Malcolmson, C., Satra, C., Kantaria, S., Sidhu, A., Lawrence, M.J., 1998. Effect of 
oil on the level of solubilization of testosterone propionate into nonionic oil-in-
water microemulsions, J. Pharm. Sci., 87 (1): 109-116 
14. Matuszewska, B., Hettrick, L., Bondi, J.B., Storey, D., E., 1996. Comparative 
bioavailability of L-683,453, a 5oc-reductase inhibitor, from a self-emulsifying 
drug delivery system in beagle dogs. Int. J. Pharm., 136, 147-154. 
15. Meyer, T., Bohler, J., Frahm, A.W., 2001. Determination of Cremophor EL in 
plasma after sample preparation with solid phase extraction and plasma protein 
precipitation, J. Pharm. Biomed. Anal., 24: 495-506 
16. Pillay, V., Fassihi, R., 1999. A new method for dissolution studies of lipid-filled 
capsules employing nifedipine as a model drug. Pharm. Res., 16 (2), 333-337. 
17. Pillay, V., Fassihi, R., 1999. Unconventional dissolution methodologies, J. Pharm. 
Sci., 88 (9): 843-851. 
18. Pozzi, F., Longo, A., Lazzarini, C., Carenzi, A., 1991. Formulations of 
ubidecarenone with improved bioavailability. Eur. J. Pharm. Biopharm., 37 (4), 
243-246. 
19. Roman, R., 1999. So you want to use lipid-based formulations in development. B. 
T. Gattefosse, 33, 51-58. 
134 
20. Serajuddin, A.T. M., Sheen, P.C., Mufson, D., Bernstein, D.F., Augustine, M.A., 
1988. Effect of vehicle amphilicity on the dissolution and bioavailability of a 
poorly water soluble drug from solid dispersions. J. Pharm. Sci., 77 (5), 414-417. 
21. Shah, N.H., Carvajal, M.T., Patel, C.I., Infeld, M.H., Malick, A.W., 1994. Self-
emulsifying drug delivery systems (SEDDS) with Polyglycolysed glycerides for 
improving in vitro dissolution and oral absorption of lipophilic drugs. Int. J. 
Pharm. 106, 15-23. 
22. Sheen, P.C.,. Kim, S.I, Petillo, J.J., Serajuddin, A.T. M., 1991. Bioavailability of a 
poorly water soluble drug from tablet and solid dispersion in humans. J. Pharm. 
Sci., 80 (7), 712-714. 
23. Sparreboom, A., Tellingen, O.V., Huizing, M.T., Nooijen, W.J., Beijnen, J.H., 
1996. Determination of Cremophor EL in plasma by pre-column derivatization and 
reverse-phase high-performance liquid chromatography, J. Chromatography B, 
681: 355-362 
24. Swenson, E.S., Milisen, W.B., Curatolo, 1994. Intestinal permeability 
enhancement: Efficacy, acute local toxicity and reversibility. Pharm. Res., 11 (8), 
1132-1142. 
135 
(.,..) 
0\ 
--..... 
Table I. Lipids used in this study 
Classification and chemical Chemical Name Trade Names Composition (% fatty acid 
structure distribution) 
Triglycerides Caprylic (Cs) I Miglyol 810 Cs: 71 C10: 29 
Capric (C1 0) triglyceride 
Glyceryl mono-/ di-esters Mono-and di-glyceride of caprylic Capmul MCM Cs: 81 C10: 18 C6: 1 
/capric acid 
Glyceryl mono-oleate Capmul GMO C1 s: 1: 80 C1s:2: 10 C1 s: 4 C1 6: 4 C1 4: 2 
Diglyceryl mono-oleate Caprol 2GO C1 s: 1: 90 C1 s:2: 3 C1 s : 3 C1 6 : I 
Polyglycerol esters 
Triglyceryl mono-oleate Capmul 3GO C1 s: 1: 90 C1 s:2: 3 C1 s : 3 C1 6 : I 
Propylene glycol esters Propylene glycol mono-caprylate Capmul PG-8 Cs: 99 C 10: 1 
Propylene glycol mono-laureate Capmul PG-12 C1 2: 98 C1 4: 2 
Propylene glycol mono-oleate Capmul PG-18 C1 s: 1: 93 C1 s:2: 3 C1 s : 3 C1 6 : 1 
* C6: Caproic, Cs: Caprylic, C10: Capric, C1 2: Laurie, C14: Myristic, C14:l: Myristoleic, C16: Palmitic, C16: l: Palmitoleic, C1s : Stearic, 
C1s:1 : Oleic, C1s 2 : Linoleic and C1 s:3: Linolenic acid 
-~ 
Table II. Calculated and measured properties of lipids used 
Lipid HLB Density (g/cm3) MW Viscosity ( cP) Dielectric constant Interfacial tension (mN/m) at 37°C 
Miglyol 810 l.5 0.9437 495 15 2.0958 12.00 
Capmul MCM 6.5 l.0022 275 65 2.1048 Not measurable 
Capmul GMO 4 0.9451 490 325 2.1574 3.16 
Caprol 2GO 5 0.9814 421 760 2.1697 2.70 
Caprol 3GO 6 0.9776 494 1090 2.1691 2.43 
V.l 
-.J 
Capmul PG-8 5 0.9387 202 1 2.0630 3.23 
Capmul PG-12 4 0.9183 258 15 2.0863 3.12 
Capmul PG-18 3.5 0.9096 340 25 2.1293 3.15 
( 
Table III. Nifedipine solubility in Simulated Gastric Fluid at 37°C containing 
Cremophor EL 
Cremophor EL(% w/v)) Solubility (mg/mL) 
0 0.0054 
0.5 0.0548 
1 0.1032 
2 0.2104 
3 0.3148 
5 0.5739 
7 0.7885 
10 1.1641 
12 1.4551 
15 1.7048 
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( Table IV. Solubility of nifedipine in lipid/Chremophor EL mixtures 
Lipid vehicle Cremophor EL Nifedipine solubility % increase in 
concentration % mg/g mean± SEMn=3 solubility 
0 3.359 ± 0.029 0 
Miglyol 810 10 4.863 ± 0.043 43 
Glyceryl tri 
20 10.183 ± 0.087 197 
30 17.940 ± 0.123 418 
caprylate (Cs) 
40 23.702 ± 0.091 577 
50 18.276 ± 0.083 415 
0 10.273 ± 0.091 0 
Capmul MCM 10 14.368 ± 0.037 39 
20 16.738 ± 0.047 61 
Glyceryl mono-
30 23.873 ± 0.089 129 
caprylate (Cs) 
40 23.720 ± 0.023 126 
50 26.478 ± 0.124 151 
0 3.115±0.111 0 
10 8.878 ± 0.094 182 
CapmulGMO 
20 11.758 ± 0.087 269 
Glycerylmono-
30 16.456 ± 0.108 411 
oleate (C1s:1) 
40 18.591±0.056 472 
50 24.825 ± 0.083 657 
0 3.026 ± 0.037 0 
Caprol 2GO 10 7.055 ± 0.148 131 
2-glyceryl mono-
20 10.221 ± 0.097 231 
30 14.657 ± 0.084 370 
oleate (C1s:1) 
40 19.548 ± 0.174 521 
50 24.143 ± 0.267 662 
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Table IV: Solubility of nifedipine in lipid/Chremophor EL mixtures (continued) 
Lipid vehicle CremophorEL Nifedipine solubility % increase in 
concentration % m_glg_ mean± SEM n=3 solubility 
0 3.193 ± 0.099 0 
Caprol3GO 10 6.217 ± 0.122 93 
20 10.679 ± 0.165 230 3-glyceryl mono-
30 12.353 ± 0.465 279 
oleate (C1 s: 1) 
40 19.385 ± 0.345 490 
50 24.304 ± 0.655 635 
0 16.983 ± 0.555 0 
10 19.256 ± 0.426 12 Capmul PG-8 
20 23.304 ± 0.457 34 
Propylene glycol 
30 27.750 ± 0.589 58 
mono-caprylate 
40 31.226± 0.891 76 
(Cs) 50 40.032 ± 0.924 123 
0 8.118 ± 0.243 0 
10 10.717 ± 0.094 30 Capmul PG-12 
20 13.287 ± 0.243 60 
Propylene glycol 30 18.792 ± 0.145 122 
mono-laurate 40 23.359 ± 0.456 173 
.1C.l2l 
50 18.055 ± 0.754 110 
0 5.068 ± 0.035 0 
Capmul PG-18 10 8.728 ± 0.216 70 
Propylene glycol 20 10.990 ± 0.556 112 
mono-oleate 30 14.683 ± 0.423 178 
40 21.050 ± 0.589 293 
(C1s:1) 50 30.176± 0.812 455 
Cremophor EL 0 58.23 ± 1.632 -
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Table V. List of parameters for Equation 2 to investigate the effect of surfactant concentration on the solubility of 
nifedipine (SN) in lipids 
Lipid R adj a (slope) SL p for goodness of fit 
Miglyol810 (Glyceryl tri-caprylate) 0.782 0.40 3.12 0.9637 
CapmulMCM (Glyceryl mono-caprylate) 0.915 0.36 10.51 0.3470 
CapmulGMO(Glyceryl mono-oleate) 0.981 0.41 3.76 0.7663 
Caprol2GO (Di-glyceryl mono-oleate) 0.994 0.42 2.57 0.1856 
-
Caprol3GO (Tri-glyceryl mono-oleate) 0.967 0.42 2.21 0.1153 
.j:::.. 
- Capmu!PG-8 (Propylene glycol mono-caprylate) 0.987 0.37 16.30 0.2789 
CapmulPG-12 (Propylene glycol mono-laurate) 0.964 0.38 7.146 0.6537 
CapmulPG-18 (Propylene glycol mono-oleate) 0.955 0.38 4.52 0.8131 
r 
Table VI. Dissolution parameters of nifedipine in various lipids (n =3) 
Lipid Dissolution rate (k)* 
(Mean± SD) 
Miglyol810 0.012 ± 0.000 
(Glyceryl tri-caprylate) 
Capmul MCM 0.254 ± 0.009 
(Glyceryl mono-caprylate) 
Capmul GMO 0.021±0.002 
(Glyceryl mono-oleate) 
Caprol2GO 0.074 ± 0.002 
(Di-glyceryl mono-oleate) 
Caprol3GO 0.081 ± 0.009 
(Tri-glyceryl mono-oleate) 
Capmul PG-8 (Propylene 0.006 ± 0.000 
glycol mono-caprylate) 
Capmul PG-12 (Propylene 0.008 ± 0.002 
glycol mono-laurate) 
Capmul PG-18 (Propylene 0.015 ± 0.001 
glycol mono-oleate) 
*k: calculated using Equation 1 
#%dissolved nifedipine at 60 minutes 
142 
Dissolution extent ( % ) 
(Mean± SD) 
50.19 ± 1.44 
96.05 ± 0.28 
79.64 ± 1.44 
76.58 ± 0.99 
73.12 ± 0.43 
30.27 ± 3.54 
31.85 ± 2.93 
45.73 ± 2.50 
( 
Table VII. Results of particle size of nifedipine in each lipid at 37°C 
Particle size (nm, mean ± SD, n=3) 
Lipid 10 min 20 min 40 min 60min 
Miglyol810 NIA* NIA* NIA* NIA* 
CapmulMCM 10 ± 0.5 12 ± 1.1 12 ± 1.5 11±0.5 
Capmul GMO 322 ± 11 328 ± 8 337 ± 12 333 ± 28 
Caprol 2GO 473 ± 36 434 ± 28 433 ± 28 454 ± 45 
Caprol 3GO 459 ± 24 419 ± 28 418 ± 32 417 ± 28 
Capmul PG-8 800 ± 4.7 786 ± 24 765 ± 27 777 ± 32 
Capmul PG-12 732 ± 26 726 ±9 728 ± 26 724 ± 5 
Capmul PG-18 727 ± 23 723 ± 21 730 ± 26 707 ± 8 
Miglyol8101 11±1.0 11±2.1 10 ± 1.3 10 ± 1.2 
Cremophor EL 
*NI A: not applicable. The mixture is too coarse to measure 
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( Figure 1. Critical micelle concentration (CMC) of Cremophor EL (n=3) 
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1. INTRODUCTION 
The use of lipid formulations generated considerable interest in the last two decades 
because the modem drugs produced are highly lipophilic as the result of High 
Throughput Screening (HTS). The lipids may improve the bioavailability of drugs 
through several mechanisms such as by enhancing their solubility/ dissolution (Pozzi 
et al., 1991; Sheen et al., 1991; Charman et al., 1992; Shah et al., 1994; Matuszewska 
et al., 1996; August et al., 1997), by homogenously dispersing the drug into the gastric 
fluid and providing and uniform absorption rate (Yamahira et al, 1979a, b, 1980) and 
by increasing lymphatic absorption (Cheema et al., 1987; Charman and Stella, 1992). 
Despite numerous studies with lipid-based system to increase the bioavailability of 
poorly soluble drugs, only a relatively few commercial formulations of lipid-based 
systems are available on the market. These are cyclosporine (Sandimmune™ and 
Neoral™, Novartis), saquinavir (Fortovase™, Roche), ritonavir (Norvir™, Abbott) and 
fat-soluble vitamins. Among the reasons for limitation of their use may be not to have 
sufficient knowledge of in vitro and in vivo performance of these type of formulations. 
Lipolysis that takes place in upper intestine is a physiological event that makes it more 
difficult to predict in vivo performance of lipid-based formulations. 
Understanding of the lipid digestion process is important in design of the lipid-based 
formulations. The digestion process involves three basic steps: (I) dispersion of lipid 
solution into the gastric media and emulsification of the solution by the gastric 
movements, (II) enzymatic hydrolysis of di- and tri-glycerides into mono-glyceride 
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and fatty acids, (III) formation of the mixed micelles with hydrolysis products and bile 
salts and ultimately absorption of lipids through the intestinal wall (Carey et al., 1983). 
Only tri-glycerides are digested physiologically. The pharmaceutical grade di-
glycerides are rare. When a mono-glyceride is used in a formulation, it is assumed that 
it skips the enzymatic hydrolysis step. Therefore, dissolution studies may be predictive 
of the bioavailability of such systems. 
Micelle formation of lipolysis products with bile salts is the crucial step that enhances 
the solubility and absorption of poorly soluble drugs. The total solubility of 
compounds such as steroids, griseofulvin, cyclosporine A, danazol, pentazocaine, 
triamcinolene and diazap""m was found to be pr0portional to taurocho1ate 
concentration, a major bile salt present in the small intestine. A linear relationship was 
shown between solubilization and partition coefficient of steroids, cyclosporine A, and 
griseofulvin (Mithani et al., 1996). 
A detailed discussion of the lipid digestion process and its impact on drug absorption 
from the gastro-intestinal tract can be found in several reviews (Eldem and Speiser, 
1989; Embleton and Pouton, 1997; 1997; MacGregor et al., 1997; Dumanli et al, 
2002). However, there are not many published studies investigated the correlation 
between in vitro lipolysis and in vivo results. MacGregor et al. (1997) briefly 
mentioned the lipolysis of progesterone that was formulated with two SEDDS and 
compared with plasma profiles an oily suspension. The AUCs of the lipid formulations 
were 8-10 times more the suspension. The SEDDS formulations formed small 
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( droplets, uniformly dispersed in the GI system and undergone lipolysis were 
I 
demonstrated good in vitro in vivo coITelation. Reymond et al. (1988a and b) described 
an in vitro study where lipid emulsion was formulated with controlled particle size and 
followed the bioavailability of drug from such emulsions in the male rats via urine 
excretion. They have concluded that in vitro lipolysis could not simulate in vivo 
performance of the formulations. 
In order to coITectly predict in vivo performance of lipid formulations, more than one 
evaluation technique such as dissolution, particle size determination and solubility of 
the drug in the lipids and GI fluids may be needed. 
In this study, the bioavailability of nifedipine from different lipid formulations was 
determined in the beagle dogs. The types of lipids were determined from our previous 
study in which in vitro dissolution performance of a nifedipine formulation in 
CapmulPG-8 (propylene glycol mono-caprylate), CapmulPG-12 (propylene glycol 
mono-laurate), CapmulPG-18 (propylene glycol mono-oleate), CapmulMCM 
(glyceryl mono-caprylate/caprate), Miglyol810 (glyceryl tri-caprylate), Caprol2GO 
(diglyceryl mono- oleate), Caprol3GO (tri-glyceryl mono-oleate) and CapmulGMO 
(glyceryl mono-oleate) was investigated (Manuscript III). Among these lipids, we 
have selected CapmulMCM, which provided the highest dissolution rate, Capmul 
PG8, which provided the lowest dissolution rate and Miglyol810, which provided 
relatively moderate dissolution rate, for the further in vivo studies. The latest lipid is a 
tri-glyceride which undergoes to lipolysis, while Capmu!MCM and Capmu!PG-8 are 
( 
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mono-glycerides and therefore are not subjected to the lipolysis process. To seek an in 
vitro and in vivo correlation, the solubility, partitioning and particle size of nifedipine 
in the given lipids were also determined. 
2. MATERIALS AND METHODS 
2. 1. Materials 
Nifedipine and butamben (an internal standard for HPLC analyses of nifedipine in 
plasma) were purchased from Sigma, Louis, MO, Capmul MCM (Mono-glyceryl 
caprylate/caprate) and Capmul PG-8 (Propylene glycol caprylate) were provided by 
Abitec, Columbus, OH. Miglyol810 (tri-glyceryl caprylate/caprate) and Cremophor 
EL (PEG-35 Castor oil,) were gifts from Sasol, NJ and BASF, Germany, respectively. 
All the lipids have GRAS (Generally Recognized as Safe) status. Methanol, 
acetonitrile, chloroform, acetone, phosphoric acid were purchased from Fisher 
Scientific., Springfield, NJ. All the chemicals were used as received. 
2.2. Methods 
2.2.1. Preparation of Formulations 
Nifedipine (100 mg) was dissolved in each lipid vehicle (4.5 g) at 25°C in a shaker. 
All formulations were in clear liquid form and there were no changes observed when 
they were kept at 4°C for a month. The components of the formulations were given in 
Table 1. The fo1mulations A-C contained 100 mg nifedipine and 45 g lipid in each 
batch. Fo1mulation D contained 100 mg nifedipine, 4.5 g Cremophor EL and 40.5 g 
Miglyol 810. Each formulation (1.1250g containing 2.5 mg nifedipine) was filled into 
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( a "000 size" hard-gel capsule sealed with a bending solution to prevent the leakage. 
The bending solution contained 20% (w/v) capsule shells, 0.8 % (w/v) Tween80 and 
distilled water and was kept at 40°C during sealing. 
2.2.2. Nifedipine Assay in the Formulations 
Nifedipine content of the each formulation was determined by an HPLC method 
described in Section 2.2.3.l. The determination was made by weighing around 0.14 g 
of the formulation that contained 0.078 mg nifedipine, diluting with methanol and 
analyzing at 238 nm. 
2.2.3. In vitro Tests 
2.2.3.1. Solubility Determination 
The solubility of nifedipine was determined in each lipid vehicle by adding an excess 
amount of the drug into 10 g of the vehicle mixture and equilibrating the mixture at 
25° ± 0.1 °C for 72 hr. The mixture was centrifuged for 10 minutes and filtered 
through a 0.45µm filter. The amount of nifedipine dissolved was determined by the 
HPLC method. 
A Hewlett Packard 1050 HPLC system with a UV detector (A. =236 nm) was used. 
The stationary phase consisted of a micro Bondapak, C 18 reverse phase column (3.9 x 
300 mm, Waters Corp., Milford, MA). The mobile phase used was acetonitrile: 
methanol: water (2: 3: 3) mixture. The samples were diluted with methanol before the 
run and the flow rate was 1.0 mL/min with 30 minutes of total run time per injection. 
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( The data acquisition was made using the software Turbochrome 6.1.1.0.0 (Perkin 
Elmer Corp, Wellesley, MA). All studies were performed in triplicates. 
2.2.3.2. Dissolution Test 
The USP II apparatus with paddle at 50 rpm and 37°± 0.1°C was used to obtain 
dissolution profiles for the nifedipine lipid capsules. Simulated gastric fluid (SGF) 
(pHl.2, 900 rnL) was used as the dissolution medium. Since the solubility of 
nifedipine is low in SGF, Cremophor EL, a nonionic surfactant, was added to the 
dissolution medium to increase the solubility of drug. Cremophor EL concentration of 
3% (w/v) was high enough to improve and maintain the solubility of nifedipine and to 
differentiate dissolution of nifedipine formulations used. Four capsules containing 
total 10-mg of drug were placed in capsule cages then dipped into dissolution vessel. 
Samples (3 rnL) were withdrawn using a syringe attached to a cannula that has a 10 µ 
filter at the tip at 3, 5, 8, 10, 15, 20, 40 and 60 minutes. The sample withdrawn was 
replaced with 3 rnL fresh dissolution medium. The amount of dissolved nifedipine was 
determined by the HPLC method as explained in Section 2.2.3.1. 
The amount of dissolved nifedipine (%)at 60 minutes was taken as the dissolution 
extent of the formulation. 
2.2.3.4. Partition Coefficient 
The partition coefficient of the drug between the formulation and the Simulated 
Gastric Fluid (SGF) USP, was obtained by mixing equal amount of formulation and 
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SGF + 3% Cremophor EL for l hr at 25°C. The phases were separated by 
centrifuging the mixtures for 10 min at 2000 rpm. The oily phase was assayed for the 
amount of the drug analyzed by the HPLC method given in Section 2.2.3.l. 
2.2.3. 5. Particle Size Measurements 
The dissolution apparatus described in Section 2.2.3.2 was used for the particle size 
measurements. Four capsules that contained a total of 10-mg drug were placed in the 
capsule cages and dipped into the dissolution medium (900 mL SGF contained 3% 
w/v Cremophor EL). Sample (5 mL) was withdrawn at 10, 20, 40 and 60 minutes and 
the particle sizes were measured using a Dynamic Light Scattering (Brookhaven 
Instrument Corp. Holtsville, NY). The measurement duration was one minute at 488 
nm and at 90° of detector angle. Polydispersity index monitored was within 0.2% 
range. 
2.2.4 In vivo Absorption Study Design 
2.2.4.1. Test Animals 
The bioavailability of nifedipine lipid formulations was tested on six fasted beagle 
dogs using a single dose crossover design. The washout period between the 
experiments was one week. The dogs were supplied by The Marshall Farms, North 
Rose, NY. They were approximately 7-10 kg in weight and 13-16 months old and 
were acclimatized for at least three weeks prior to study. 
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( The study group consisted of 3 males and 3 females. Each dog had an ear tattoo and 
was housed individually in a stainless steel cage that has an identification card 
showing compound number, study number, dose level and dog number and sex. Room 
temperature and humidity was maintained at approximately 72° ± 4°F and 50% ±19%, 
respectively. The animal room was on an approximate 12-hour light/dark cycle. Dogs 
were exercised outside the cage at least three times a week for at least 15 minutes. 
2.2.4.2. Dosage forms, frequency and method of dosing 
The dogs were fasted overnight prior to experiment. Each dog received four 2.5 mg 
nifedipine capsules (Details of the protocol were given in Table II). Each dog received 
approximately 500g Teklad Glohl Certified 21 % protein Dog Diet 2021C f hours 
after dosing. Water, purified via reverse osmosis (RO), was available ad libitum by 
means of an automatic watering system. The RO water supply for each active animal 
room was monitored for bacterial contamination at least once a month by the 
Department of Laboratory Animal resources. In addition, chemical analysis of water 
was performed at approximately quarterly intervals by the Environmental Monitoring 
and Support Laboratory. No contaminants expected to interfere with the study were 
known to be present in the feed or water. 
2.2.4.3. Blood sampling 
Blood samples (lmL) were collected via jugular vein from each dog at 0, 1, 2, 3, 6, 10 
and 24 hours and placed into glass tubes containing EDTA used as an anticoagulant. 
The tubes were kept at 4°C to prevent decomposition. The plasma was separated from 
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( the whole blood with centrifugation at 4°C, transferred to screw- cap vials and was 
kept frozen in a -70°C freezer until assay time. 
2.2.5. Assay of nif edipine in plasma 
Nifedipine in all samples was assayed using a modified version of the HPLC method 
described by Mehta et al. (2002). In this method, a vortex mixer (Scientific Industries 
Inc., Bohemia, NY) was used to equilibrate the frozen samples at room temperature. 
Methanol (100 µl) containing 2 µg/mL butamben (as the internal standard) and 
acetonitrile (2 mL) were added to 0.5 mL plasma and vortex mixed for 30 minutes. 
After centrifugation at 4000 rpm for 15 minutes with a Hermie Centrifuge 
(ModelZ382K, Denville Scientific, Metuchen, NJ), 2 mL of supernatant was 
transferred into a test tube containing 1 mL of distilled water. Acetone-chloroform 
mixture (4.5 mL, 1:1 v/v) was added to this mixture and was shaken for 1 hour. This 
solution was further centrifuged at 4000 rpm for 15 minutes to separate organic phase 
from aqueous phase. The aqueous phase was discarded. The organic phase transferred 
into an amber color test tube, and dried in a Turbovap LV ZW700 evaporator (Zymark 
Corp., Hopkington, MA) at 45°C for an hour under nitrogen. The residue was 
dissolved in 100 µI mobil phase, vortex-mixed for 30 seconds, transferred into 
Eppendorf tubes and centrifuged at 14000 rpm for 10 min. The aliquot (25µ1) obtained 
was injected to the HPLC system for nifedipine determination. 
A Hewlett Packard 1050 HPLC system with a UV detector (A =238 nm) was used. 
The stationary phase used was a reverse phase Zorbax RX-C18, 5-micron, 25cm x 4.6 
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( mm column (Agilent Tech., Palo Alto, CA). The column temperature was kept at 
55°C. The mobile phase consisted of 0.01 M disodium hydrogen phosphate buffer-
methanol (45 :55, v/v) mixture. The pH of the buffer was adjusted to pH=6. l with 40% 
phosphoric acid. Run time used was 20 minutes and the flow rate was 0.8 mUmin. 
The data acquisition was made using the software Turbochrome 6.1.1.0.0 (Perkin 
Elmer Corp, Wellesley, MA). 
The calibration graph was obtained by adding nifedipine solution in methanol to drug-
free plasma. Nifedipine plasma solutions were prepared at concentration of 0, 10, 20, 
40, 80, 120, 160, 200 and 240 ng/mL and stored in a -70°C freezer for pending 
analysis. The samples we1 ~ processed as describ2d above. The ratios c ~ the peak area 
of nifedipine to that of butamben were used to construct a calibration graph, 
Appendix , Figure16. CV for precision of the experiment was within 2%. 
2.3.6. Pharmacokinetic analysis 
Pharmacokinetic parameters were calculated from nifedipine plasma concentration. 
Maximum plasma concentration (Cmax), time of occurrence of Cmax (Tmax) and 
area under the curve (AUC0_24 h) was calculated using WinNonlin software by 
Pharsight Corporation (Mountain View, CA). 
2.3.7 Statistical Analyses 
Results for plasma concentrations were presented as mean ± SEM (standard error 
mean). Statistical comparisons of pharmacokinetic parameters were performed using t-
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test for each pair. JMP Statistical Software version 4.0.4 (SAS Institute Inc, Cary, NC) 
has been used for analysis. 
3. RESULTS AND DISCUSSION 
The assay demonstrated that nifedipine lipid formulations contained 99-102 % of the 
original nifedipine loading. The plasma concentrations obtained after dosing each 
animal with respective formulations are presented in Table III. One of the female 
dogs (F4) vomited the Formulation A 10 minutes after the administration. Therefore, 
the results obtained from this dog excluded from further calculations. 
Table IV shows the mean pharmacokinetic parameters (Cm:-.x, T max, AUCo-24 h) of the 
respective formulations and Figure 1, the plasma concentration profiles obtained 
during 10 hours following administration. As seen in Table IV and Figure 1, Tmax 
values obtained from formulation A, B, C and D were not significantly different from 
each other (p>0.05) demonstrating that neither the lipids nor the surfactant added 
influences the absorption time of nifedipine. On the other hand, Cmax and AUCo-24 
values of formulations were significantly different from each other (p<0.05). The 
highest plasma profile was obtained with nifedipine formulations containing 
Miglyol810/Cremophor EL (9/1) and the lowest with the formulation containing 
CapmulPG-8. The highest Cmax and AUC0_24 are the result of the micelle formation 
ability of Cremophor EL in GI medium and thus improved solubility of nifedipine. 
The bioavailability of nifedipine from formulation Dis followed by C>B>A. The 
reason for higher bioavailability with Miglyol810 (glyceryl tri-caprylate) compared 
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r with CapmulMCM (glyceryl mono-caprylate/caprate) can be explained by Iipolysis. 
' 
Miglyol810 is a tri-glyceride and broken down to mono-glyce1ide and fatty acids 
during lipolysis whereas CapmulMCM is a mono-glyceride and stays as it is during 
the digestion process. Although both form micelles with bile salts, digestion of 
Miglyol810 will generate higher amount of fatty acids. Therefore, the amount of 
micelles produced in the presence of bile salts with Miglyol810 will be higher than the 
micelles formed with CapmulMCM. Sek et al. (2002) also clearly demonstrated that 
the effect of bile salt on Miglyol812 was more pronounced than on CapmulMCM by 
an in vitro lipolysis experiment. A higher bile salt concentration can result in more 
micelles for solubility, partitioning and subsequent absorption of nifedipine. 
Therefore, in the presence of Miglyol810, higher plasma concentration of nifedipine 
was obtained. ( 
The dissolution profiles of the same formulations demonstrated a different picture in 
simulated gastric fluid as shown in Figure 2. The Formulation B containing 
CapmulMCM and D containing CremophorEL provided the highest dissolution rate 
and extent while Formulation C containing Miglyol810 provided 50% release for 
nifedipine after 60 minutes. The lowest dissolution profile was obtained with 
Formulation A containing Capmul PG-8 which also provided the lowest 
bioavailability of nifedipine. The only significant difference observed between in vitro 
dissolution and in vivo plasma concentration profiles was with Formulations B and C. 
Formulation B containing CapmulMCM provided the higher dissolution profile than 
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( Formulation C with Miglyol810. The opposite result observed the in vivo test was the 
result of lipolysis that was absent during the dissolution tests. 
As the result of the findings, it can be said that the dissolution test by itself is not 
sufficient to predict the in vivo performance of formulations containing digestible 
lipids. 
The differences of the effects of CapmulMCM and CapmulPG-8 can be explained by 
the contribution of the hydrophilic pait to the lipid solubility and dissolution of 
nifedipine (Manuscript II and III). CapmulMCM is a glyce1ide ester of caprylic/capric 
acid and has a molecular weight of 275. CapmulPG-8 is a propylene glycol ester of 
caprylic acid and has a molecular weight of 202. Both lipids are surface active. The 
dissolution of samples containing either lipid is carried out in an environment contains 
3% Cremophor EL. Under these conditions, CapmulMCM formed particles of 
approximately 12 nm and Capmul PG-8 around 700 nm, Table V. This may be one for 
the reasons of the differences observed in dissolution, Figure 2. Similarly, the 
formulation that was dispersed to larger particle size emulsion performed poorer 
bioavailability, Figure 1. The particle size effect may be true for the formulations that 
contain only mono-glycerides. However, it is not relevant for comparison of 
Formulations C and B. If the particle size is a factor, the lower bioavailability should 
be obtained for Formulation C containing Miglyol 810. 
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( The effect of solubility of nifedipine in lipids on bioavailability also showed an 
inverse effect for the formulations without surfactant. The highest nifedipine solubility 
was obtained in CapmulPG-8 and this formulation provided the lowest bioavailability. 
Miglyol810 provided the lowest solubility for nifedipine, but the highest 
bioavailability among the lipids excluding the formulation with surfactant, Table V. 
This property affects the partitioning of nifedipine from the formulations to the 
dissolution medium. Partitioning values were also included in the same table. It 
provided the similar effect on bioavailability of nifedipine as dissolution does. 
4. CONCLUSION 
Bioavailability of nifedipine obtained with different lipid formulations in beagle dogs 
showed that the type lipid and surfactant used in the formulation plays an important 
role. Dissolution is a good predictor for the in vivo performance of nifedipine lipid 
formulation when it was formulated with non-digestible lipids (mostly mono-
glycerides). 
Although, the solubility of nifedipine in lipids, particle size of the formulation in 
dissolution medium and partitioning of the drug from the formulation to dissolution 
medium seem to affect the in vivo performance of the drug, dissolution rate and extent 
of the formulation and digestibility of the lipid used in the formulations played the 
major roles in bioavailability of nifedipine from lipid-based formulations. 
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Table I. Lipid formulations that were used in the in vivo studies 
Formulation A B c D 
Nifedipine 100 mg 100 mg 100 mg 100 mg 
CapmulPG-8 45 g 
Capmul MCM 45 g 
Miglyol810 45 g 40.5 g 
Cremophor EL 4.5 g 
171 
I Table II. In vivo study experimental design (crossover study in fasted beagle \ 
dogs) 
Formulation Dose (mg/dog) Number of Animal Numbers 
capsules Male Female 
A 10 4 3 3 
One week wash-out period 
B 10 4 3 3 
One week wash-out period 
c 10 4 3 3 
One week wash-out period 
D 10 4 3 3 
172 
( Table III. Nifedipine plasma concentrations (ng/mL) I 
Formulation A 
Time (hr) Ml M2 M3 F4 F5 F6 Mean SD SEM 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0.5 7.11 7.10 6.23 0.00 11.73 21.31 10.70 6.32 2.58 
1 12.99 6.90 13.05 0.00 17.92 84.47 27.07 32.33 13.20 
2 7.18 5.64 9.12 0.00 10.23 58.50 18.13 22.63 9.24 
3 0.00 0.00 5.09 0.00 6.80 23.97 11.95 10.44 4.26 
6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Formulation B 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0.5 19.46 27.45 38.20 14.93 9.44 34.55 24.01 11.31 4.62 
1 9.91 28.12 31.41 22.50 48.19 67.23 34.56 20.28 8.28 
2 19.23 18.12 32.27 19.22 21.24 19.93 21.67 5.29 2.16 
3 8.71 10.14 27.10 16.35 19.07 18.76 16.69 6.71 2.74 
6 8.27 0.00 13.56 0.00 13.05 0.00 11.63 2.92 1.19 
10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
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( Table Ill: Nifedipine plasma concentrations (ng/mL) (continued) 
' 
Formulation C 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0.5 15.34 61.28 47.73 89.32 12.27 72.27 49.70 30.98 12.64 
1 6.56 61.50 77.97 66.12 8.75 56.42 46.22 30.72 12.54 
2 5.56 47.75 57.04 82.63 13.13 52.55 43.11 28.90 11.80 
3 0.00 34.25 25.88 51.03 18.65 55.63 37.09 15.91 6.49 
6 0.00 20.02 6.40 19.84 7.46 21.63 15.07 7.47 3.05 
10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Formulation D 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
0.5 141.78 47.37 110.87 136.30 115.80 80.60 105.45 35.77 14.60 
1 57.84 38.94 48.63 46.61 69.23 54.09 52.56 10.43 4.26 
2 18.58 47.49 24.85 44.95 89.69 37.35 43.82 25.13 10.26 
3 16.91 13.87 33.98 32.81 76.15 16.90 31.77 23.40 9.55 
6 5.52 6.41 32.02 19.31 53 .54 10.75 21.26 18.66 7.62 
10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
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Table IV. Mean pharmacokinetic parameters of nifedipine lipid formulations with 6 beagle dogs 
Formulation Tmax ± sem 1 
(hr) 
A (CapmulPG-8, propylene glycol 
0.9 ± 0.1 
mono-capry late) 
B (Capmul MCM, glyceryl mono-
0.83 ± 0.11 
caprylate/caprate) 
C (Miglyol8 l 0, glyceryl tri-caprylate) 
0.75 ± 0.11 
D (Miglyol8 l O/Cremophor EL, 9/ I) 
0.58 ± 0.08 
1 p < 0.1806 Tmax values are not significantly different 
2 p < 0.006 Cmax values are significantly different 
3 p < 0.0235 AU Cs are s ignificantly different 
Cmax ± sem2 AUCo-24 ± sem3 
(ng/mL) (ng.h/mL) 
23.66 ± 11.03 54.47 ± 18.80 
37.28 ± 7.39 154.64 ± 22.81 
55.84 ± 12.83 252.31 ± 54.24 
105.47 ± 14.59 362.44 ± 108.05 
' 
Digestibility 
Yes 
Skips 
Skips 
Inhibited 
---------
-
Table V. Summary of in vitro results for nifedipine lipid formulations 
Formulation Solubility Dissolution Partition Particle size 
(mg/g) (%)at 60 min coefficient (o/w) (nm) 
Miglyol 810 3.36 ± 0.03 50.19± 1.44 5.6 ± 0.45 Coarse 
Capmul MCM 10.27 ± 0.09 96.05 ± 0.28 2 ± 0.18 11.6 ± 0.5 
Capmul PG-8 16.98 ± 0.55 30.27 ± 3.54 9.6 ± 0.76 777 ± 32 
Miglyol 810/ 4.86 ± 0.04 97.23 ± 2.52 1.1 ± 0.02 10 ± 1.0 
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Figure l: Nifedipine plasma profiles with four formulations 
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Figure 2: Dissolution ofnifedipine from the formulations used for in vivo study 
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Figure 1. Calibration curve for griseofulvin in acetone 
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Figure 2. Standart curve for HPLC analysis of nifedipine 
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Figure 3. FT-IR spectrum of nifedipine in mineral 
n226.90 
1679.48 
1 0 -
09 - 1531 .98 
08-
07-
"' 06-c: 
"' ::;; 
'° "' Qj 0.5 -0 
"' :.'. 
0.4 -
( 
3500 3000 1500 1000 
Wavenumbers (cm-1) 
182 
Figure 4. FT-IR spectrum of griseofulvin in mineral 
12-
11- 1mss 
1.0-
09-
OB-
01 - 11li 39 
06- 1009 51 
05 -
35(lJ 2flll 20CIJ 1:ol Hill 
Wavenumbers (cm-1) 
( 
183 
( 
Figure 5. FT-IR spectrum of oleic acid 
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Figure 6. FT-IR spectrum of Captex GTO 
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Figure 8. FT-IR spectrum of Capmul MCM 
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Figure 11. FT-IR spectrum of Caprol3GO 
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Figure 12. FT-IR spectrum of Capmul PG-8 
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Figure 13. FT-IR spectrum of Capmul PG-12 
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Figure 14. FT-IR spectrum of Capmul PG-18 
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Figure 15. FT-IR spectrum of Captex200 
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Figure 16. Standard curve for nifedipine plasma calculation 
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